Sharon M Castellino

EMORY UNIVERSITY SCHOOL OF MEDICINE
STANDARD CURRICULUM VITAE

Revised: 09/18/2025

1. **Name:** Sharon M. Castellino, MD, MSc

2. **Office Address:**
   Aflac Cancer & Blood Disorders Center
   Children's Healthcare of Atlanta
   HSRBII N-348
   1750 Haygood Drive, Atlanta, GA 30322

3. **Current Titles and Affiliations:**
   a. **Academic Appointments:**
      1. **Primary Appointments:**
         2021 - present:
         Professor of Pediatrics, Pediatric Hematology/Oncology
         Emory University School of Medicine, Atlanta GA

   b. **Clinical Appointments:**
      1. 2015 - present: Program Leader, Leukemia/Lymphoma Program, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta GA

   c. **Other Administrative Appointments:**
      1. 2022 - present: Scientific Chair, Hodgkin Lymphoma Committee, Children's Oncology Group
      2. 2024 - present: Mark R. Hudgens Chair for Clinical Research, Children's Healthcare of Atlanta

4. **Previous Academic and Professional Appointments:**
   a. 1998 - 2003: Assistant Professor, Pediatrics, Hematology/Oncology, East Tennessee State University (ETSU) – Quillen College of Medicine, Johnson City, TN
   b. 1999 - 2004: Adjunct Clinical Faculty, St. Jude Children's Research Hospital, Memphis, TN
   c. 2003 - 2004: Associate Professor, Pediatrics, Hematology/Oncology ETSU – Quillen College of Medicine, Johnson City, TN
   d. 2004 - 2005: Associate Professor with Tenure, Pediatrics, ETSU – Quillen College of Medicine, Johnson City, TN
   e. 2006 - 2015: Founder and Director, AWAKE Long-Term Follow-up Program for Pediatric Cancer Survivors, Brenner Children's Hospital, Winston-Salem, NC
   f. 2004 - 2009: Assistant Professor, Pediatrics, Hematology/Oncology Wake Forest University School of Medicine, Winston-Salem, NC
   g. 2009 - 2015: Associate Professor, Pediatrics, Hematology/Oncology Wake Forest University School of Medicine, Winston-Salem, NC
   h. 2012 - 2015: Adjunct Associate Professor, Dept. of Epidemiology and Prevention, PHS, Wake Forest School of Medicine, Winston Salem, NC
   i. 2012 - 2015: Adjunct Associate Professor, Hypertension Center, Wake Forest School of Medicine, Winston Salem, NC

j. 2015 - 2017: Adjunct Associate Professor, Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC
k. 2015 - 2021: Associate Professor, Pediatrics, Hematology/Oncology, Emory University School of Medicine, Atlanta GA

5. **Previous Administrative and/or Clinical Appointments:**
   a. 2004-2015: Director, Childhood Cancer Survivorship program, Brenner Children's Hospital Wake Forest University School of Medicine, Winston-Salem, NC

6. **Licensures:**
   a. 1994-present North Carolina MD
   b. 1998-2005 Tennessee MD (inactive)
   c. 2015-present Georgia MD

7. **Boards and Specialty Boards:**
   a. 1995 American Academy of Pediatrics (AAP); Diplomate (recertified 2002)
   b. 1999 AAP-Pediatric Hematology-Oncology; Diplomate (active-recertified 2005;2015)

8. **Education:**
   a. 1982-84 The N.C. School of Science and Mathematics, Durham, NC
   b. 1984-88 Bachelor of Arts - Biochemistry, Magna Cum Laude, with Highest Honors, Mount Holyoke College, South Hadley, MA
   c. 2005-08 Masters in Science - Health Outcomes, Wake Forest School of Medicine, Winston-Salem, NC

9. **Postgraduate Training:**
   a. 1992-94 Internship, Residency (Post grad Yr. 2), The Children's Hospital, Boston, MA
      Program Director: Fred Lovejoy, MD
   b. 1994-95 Residency (PGY3), Duke University Medical Center, Durham, NC
      Program Director: Thomas Kinney, MD
   c. 1995-98 Fellowship-Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC
      Program Director: Phillip Rosoff, MD
   d. 2008-12 Postdoctoral Fellow, Cancer Survivorship, Wake Forest University, Winston-Salem, NC (T32; PI Avis)

10. **Continuing Professional Development Activities:**
   a. Faculty Workshop on Ambulatory and Inpatient Teaching, ETSU, Millennium Center, Johnson City, TN 2002
   b. Grant Writing Class, George Washington University, Washington, DC, 2010
   c. Pediatric Department Education Retreat, WFUSOM Winston-Salem, NC Oct. 2007
   d. American Academy of Pediatrics – Maintenance of Cycle certification 2014; 2019
   e. Career Development for Women Leaders, Office of Women in Medicine and Science, WFU SOM, 2014-15
   f. American Society of Pediatric Heme/Onc Board Review Course- CME Module on Educational Methods, 2015
   g. Georgia Clinical and Translational Sciences (CTSA) DISC assessment workshop for Mentors and Mentees, Emory University School of Medicine, Atlanta GA September 2019
   h. CIMER (Center for the Improvement of Mentoring Experience) Workshop, COG, March 14, 2023, Chicago, IL

11. **Society Memberships:**
    a. American Academy of Pediatrics, 1996-2008
    b. American Society of Hematology, 1999-2010, 2015-present
    c. American Society of Pediatric Hematology/Oncology, 1999-present
    d. Pediatric Oncology Group/Children's Oncology Group (COG), 1999-present
    e. American Society of Clinical Oncology, 1999-2011, 2018- present
    f. Society of Pediatric Research, 2008-2013
    g. American Association of Cancer Research (AACR), 2024-present

12. **Committee Memberships:**
    a. **National and International:**
        1. Children's Oncology Group (COG) Hodgkin Lymphoma (HL) Disease Committee, 2007-present
            i. Study Chair AHOD1331 2013-2022
            ii. Pediatric Study Chair S1826 2019-present
        2. COG Leadership: Scientific Chair – HL Committee, 2022- present
        3. COG Nominating Committee, 2025-present
        4. COG representative to CTEP Social Determinants of Health (SDOH) committee, 2024-present
        5. COG Nominating Committee 2025- present
        6. COG Long-term Follow-up Guidelines Taskforce:
            i. Oral/Dental/GI/Hepatic Screening Guidelines, 2004-present
                (a) Co-Chair 2004-2008
                (b) Chair 2009-2018
                (c) Guidelines Expert panel 2019- present
        7. COG Young Investigator Committee, 2007-2012
        8. Childhood Cancer Survivor Study: Cancer Control Interventions Steering Committee, 2010-2011
        9. COG Cancer Control Steering Committee, 2010-present
        10. COG HL Disease Steering Committee 2014- present
        11. Program Committee - North American Symposium on late Complications after Childhood Cancer, 2018-present
        12. Pediatric Cancer Data Commons- NODAL- HL data harmonization leadership 2019-present
        13. International Guidelines Harmonization Group (IGHG) – Late Hepatotoxicity in childhood cancer survivors, 2019 – present
        14. International Society of Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL) Committee Scientific Advisory Board, 2019-present
        15. COG Cancer Care and Delivery Research (CCDR) Steering Committee, 2019- present
        16. GLOW - Lymphocyte predominant Hodgkin Lymphoma consortium– Steering Committee
        17. Pediatric Cancer Data Commons (Data for the Common Good)- NODAL- Hodgkin Lymphoma- Steering Committee 2021-present
        18. ASPHO Mid Career Mentoring Program mentor, 2023- present
        19. American Association of Cancer Research (AACR): Pediatric Cancer Working Group (PCWG) Steering Committee, 2024- present
        20. Leukemia and Lymphoma Society – Board of Directors , 2024- present
        21. Lymphoma Research Foundation (LRF) - Adolescent and Young Adult (AYA) Lymphomas Consortium, 2024-present
        22. Lymphoma Research Foundation (LRF) - Scientific Advisory Board (SAB), 2024-present

    b. **Regional:**

1. NC Cancer Partnership-Adolescent and Young Adult (AYA) Advisory Committee, 2008
2. Georgia Cancer Plan – Pediatric and AYA Working Group, 2025

c. **Institutional:**
1. Domestic Affiliate physician liaison - St. Jude Children's Research Hospital 1999-2004
2. Faculty Search Committees 1999-2004 (Chair- Adolescent Medicine Search)
3. Pediatric Residency Training Committee, ETSU, 1998-2004
4. South West Virginia Pediatric Conference Planning Committee - Department of Pediatrics, ETSU 2000-2004; Course Director 2001-2004
5. Student Research Forum Task Force, ETSU SOM 2003-2004
6. Children's Oncology Group, East Tennessee State University (ETSU), Institutional Principal investigator (PI), 2003-2004
7. Comprehensive Cancer Center (member), Wake Forest University, 2004-2015
8. Children's Oncology Group, Wake Forest University, Institutional PI - 2013-2015
9. Protocol Review Committee, WFU Comprehensive Cancer Center, 2013-2015
10. Co-Director, Pediatric Department Grand Rounds, Wake Forest Baptist Medical Center, Winston Salem, NC 2014-2015
11. Faculty Senate-Wake Forest University, 2014-2015
12. Faculty Representative Council-Ex Officio, Wake Forest Baptist Hospital, 2014-2015
13. Research Operations Committee-Wake Forest School of Medicine, 2014-2015
14. WFU Comprehensive Cancer Center, Internal Advisory Board, 2015
15. Department of Internal Medicine WFU SOM, Research Day Judging Committee, 2015
16. Executive Committee, Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, 2015-present
17. Faculty Search Committees Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University 2015-present,
18. Service Line Operations Committee, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, 2015-present
19. Founder and co-director Leukemia and Lymphoma Biorepository - Aflac Cancer and Blood Disorders Center, Emory University, Children's Healthcare of Atlanta, 2016- present
20. Member, Winship Cancer Institute, Emory University, Atlanta GA, 2016-present
21. Diversity Equity and Inclusion Committee - lead on taskforce for Research and Outcomes - Aflac Cancer and Blood Disorders center, CHOA, Atlanta GA. November 2020- present
22. Department of Pediatrics Promotions Committee, Emory University, Atlanta GA, 2021- 2024

13. **Peer Review Activities:**
a. **Grants:**
1. **National and International:**
   i. Reviewer: National Cancer Institute ZRGI CB-L(55) Special Emphasis Panel - Developmental Pharmacology (Scientific Review officer: Janet Larkin, PhD) 2013
   ii. Reviewer: St. Baldrick's Childhood Cancer Foundation Research Grants, 2014, 2015, 2017
   iii. Reviewer: Institute National du Cancer, Research Projects in Social and Human Sciences, Epidemiology and Public Health, Paris, France 2015, 2016
   iv. Reviewer: National Cancer Institute Subcommittee J – Career Development Awards (Scientific Review officer: Robert Bird), Nov. 2015
   v. Reviewer: Children with Cancer UK, Great Ormond St., London United Kingdom, March 2016
   vi. Medical Advisory Board Member: When Everyone Survives (WES), Leukemia Research Foundation. Gwinnett, GA. 2017 - 2021.

vii. Reviewer: NCI Special Emphasis Panel/Scientific Review Group ZRG1 PSE-W (02) M (SRO Kate Fothergill, PhD), March 2018
viii. Reviewer: NCI Clinical and Translational R21 and Omnibus R03 Review Group: SEP-5 (ZCA1 SRB-5 O1) panel, June 2018 (SRO Jennifer Schiltz, PhD (NIH/NCI))
ix. Reviewer: NCI Clinical and Translational Exploratory/ Developmental Studies and Small Grants Program for Cancer Research, April 2019 (SRO Jeffrey E. DeClue, Ph. D)
x. Reviewer: NCI Symptom Management and health related quality of Life Steering Committee, Sept. 28,2021 (SRO Yvette Ortiz)
xi. Reviewer: NCI R34/U34 Clinical Trials Planning Program (ZCA1 TCRB-V), January 23, 2024 (SRO Eduardo Chufan)

2. **Institutional:**
   i. Member-Institutional Review Board - Johnson City Medical Center, 1999-2003
   ii. Intramural Grant Review Committee, Wake Forest University School of Medicine, 2006-2010
   iii. Comprehensive Cancer Center Pilot Grants, Wake Forest University School of Medicine, 2006-2015
   iv. Intramural Grant Review Committee, Wake Forest University School of Medicine, 2014-2015
   v. URC Biological & Health Sciences Sub-committee, Emory School of Medicine, 2016, 2017
   vi. Chair Study Section - Clinical and Translational Research (CCTR) Pediatric Department Pilot Awards, Emory School of Medicine, May 2019
   vii. Aflac Cancer Center Peach Bowl LegACy Fund Grants Review Committee, Emory School of Medicine May January 2020, September 2020; January 2025
   viii. When Everyone Survives Grants Review Steering Committee, Emory School of Medicine, Winship Cancer Center, Atlanta GA, 2017-2021
   ix. Donaldson Trust Grants, Winship Cancer Center, Emory School of Medicine, Atlanta GA, December 2020

b. **Manuscripts:**
   1. Journal of Pediatric Hematology/Oncology 2007-present
   2. Cancer 2008-present
   3. Cancer Epidemiology Biomarkers and Prevention 2021-present
   4. Journal National Cancer Institute 2008-present
   5. Neuro-Oncology 2008-present
   6. Journal of General Internal Medicine 2009
   7. Journal of Clinical Oncology 2009-present
   8. Psycho-Oncology 2009-present
   9. Journal of Health Psychology 2010
   10. Thorax 2011
   11. Journal of Cancer Survivorship 2011- present
   12. Family and Community health 2012
   13. Blood 2012-present
   14. European Journal of Cancer 2012-present
   15. Pediatric Blood and Cancer 2012-present
   16. Indian Journal of Cancer 2013
   17. JAMA Oncology 2015-present
   18. New England Journal of Medicine 2020-present
   19. Journal of the American Medical Association 2023-present

c. **Conference Abstracts:**
   1. **National and International:**
      i. North American Symposium on late Complications after Childhood Cancer, Atlanta, GA, June 2019, June 2023
      ii. International Society of Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL) meeting, Berlin, Germany 2020; Memphis TN 2023; Berlin 2025
      iii. ISLCCC program committee, Lucerne SWZ June 2024, Seattle 2025
      iv. American Association for Cancer Research Annual Meeting 2025 Chicago IL

14. **Editorships and Editorial Boards:**
   a. Journal of Cancer Survivorship, Associate Editor, 2015- 2017
   b. The PDQ Pediatric Treatment Editorial Advisory Board, National Cancer Institute 2017
   c. Journal of Clinical Oncology, Editorial Board, 2019-2021
   d. Journal of Clinical Oncology Mentor for peer reviewer mentoring program, 2020-2021

15. **Consultantships/Advisory Boards:**
   a. Pediatric Lymphoma Scientific Advisory Board, SeaGen Inc., 2023
   b. Pediatric and AYA Lymphoma Advisory Board, Bristol Meyers Squibb, 2024

16. **Organization of Conferences:**
   a. **National and International:**
      1. **Administrative Positions:**
         i. Organizing committee member: North American Symposium on Late Complications After Childhood Cancer (NASLCCC), 2019-present
         ii. Committee member, abstract reviewer: International Society of Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL), Berlin, Germany 2020 (postponed – COVID19 pandemic); Committee member, Virtual Meeting 2021
         iii. ISCAYAHL, organizing committee, co-host, 2023, Memphis, October 2023
         iv. ISCAYAHL, organizing committee, co-organizer, 2025, Berlin October 2025

      2. **Sessions as Chair:**
         i. Session chair: American Society of Clinical Oncology, Chicago, IL 2018; 2024
         ii. Session chair: International Society of Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL), Berlin, Germany 2020 (postponed – COVID19 pandemic)
         iii. Session co-chair: Pediatric Cancer – Clinical Investigations Section, Mini-symposium "Advances in Pediatric Cancer- From Bench to Bedside" - American Association for Cancer Research (AACR) Annual Meeting, Chicago IL, 2025

   b. **Regional:**
      1. **Administrative Positions:**
         i. Course Director/Conference Chair 2001-2004 - South West Virginia Pediatric Conference, Abingdon VA
         ii. Co-Director, AYA Survivorship Conference, Wake Forest Comprehensive Cancer Center, Winston-Salem, NC April 2014

   c. **Institutional:**
      1. **Administrative Positions:**
         i. Co-Director: Pediatric Department Grand Rounds, Wake Forest Baptist Medical Center, Winston Salem, NC 2014-2015

17. **Clinical Service Contributions:**
    a. Program leader of the Leukemia/Lymphoma (LL) Program at Emory University/Aflac Cancer and Blood Disorders center at CHOA since 2015. The program is currently one of the largest clinical LL programs in the country and sees 151-163 new patients a year and 6,724- 7,900 outpatient visits a year and has grown rapidly since 2015. The service oversight includes standardization of clinical practice across 2 campuses Scottish Rite and Egleston; now all at 1 campus – Arthur M Blank Hospital), including a procedure sedation clinic service (for lumbar punctures and bone marrows). My role also involves recruitment of faculty, mentorship of junior faculty and advance practice practitioners, oversight of scholarship and oversight of clinical operations for inpatient and outpatient care across 2 campuses (Scottish Rite; Egleston). Under my leadership, the LL program has increased clinical research and translational research and academic productivity. We enroll over 70% of our newly diagnosed patients onto a clinical trial, primarily though the Children's Oncology Group. Upon my arrival I created a clinical LL database (currently tracking > 600 LL patients) and an annotated marrow and blood biorepository. I have also been a key contributor to the founding of the High -Risk Leukemia program, which is a partnership between the LL team and the Hematopoeitic Stem cell and Cellular Therapies team. I have also been the vice chair of the Aflac precision medicine program (APMP) protocol for oncology patients and have worked to successfully advance the infrastructure and academic growth of this program since 2018 (2018. -2024). In addition, we have partnered with three other oncology programs to initiate a precision medicine consortium program in 2018.
    b. Hodgkin Lymphoma: On a national/international level I have had the opportunity to lead two practice-changing phase 3 randomized clinical trials for pediatric and adolescent patients with Hodgkin Lymphoma. I was appointed as the Scientific Chair of the Children's Oncology Group Hodgkin Lymphoma Committee, effective in March 2022 where I set and lead the scientific priorities for development of clinical trials and studies to advance the treatment of Hodgkin Lymphoma in children, adolescents, and young adults (AYA).

18. **Community Outreach:**
    a. **General:**
        1. Physician Volunteer- Bridge over Troubled Waters Mobile clinic. Boston, MA 1992-94
        2. School Board Member- St. Mary's School, Johnson City TN, 2001
        3. Health Fair, Boone's Creek Elementary School, Johnson City TN. 2002
        4. Hematopoietic Stem Cell Transplantation in Children, Rotary Club of Johnson City, Feb. 2003
        5. St. Mary's Church – Children's Liturgy Committee, Johnson City TN 2003
        6. Surviving Childhood Cancer. Speaker - Picollo Fund Seminar, WFUCCC, 2007
        7. Brett's Ride for Rhabdomyosarcoma, Hickory, NC 2007-2009
        8. St. Baldrick's Annual Head Shaving fund raiser, Finnegan's Wake, Winston-Salem NC, 2009-2014.
        9. Panel Speaker at Temple Emmanuel viewing of "Living Downstream", Dec. 2011
        10. Keynote Speaker at Brandon's Buddies fundraiser luncheon, Clemmons NC, May 2012
        11. St. Baldrick's Childhood Cancer Shavee, Winston-Salem NC, September 2014
        12. Career Day Speaker – NC School of Science and Mathematics, Durham NC – 2014
        13. Director of Events - Student of the year Campaign- Leukemia Lymphoma Society – Georgia Chapter- 2018-2019
        14. Panelist on Women in Healthcare- Make her Day- Atlanta Girls School, Atlanta, GA-2019
        15. Leukemia Lymphoma Society - Nursing Conference- April 2020 (postponed due to

COVID19 pandemic)

16. Medical Alumni Council – Duke University School of Medicine 2020- present
17. Panelist- Mentorship and Sponsorship- Duke University Undergraduate chapter, American Medical Women's Association. Virtual. February 20, 2022
18. Panel Speaker- Learning and Living with Childhood cancer – A virtual Education program for Parents and Survivors. Leukemia Lymphoma Society webinar series , Sept. 29, 2022
19. Coping with Lymphoma as an Adolescent and Young Adult (AYA) – 2022 North American Educational Forum on Lymphoma. Lymphoma Research Foundation. October 30, 2022
20. Maximizing our clinical Practices in Hodgkin Lymphoma:Treating Pediatric Patients with Hodgkin Lymphoma: Differences and Similarities with Adult Patients, ASH Satellite Symposium, New Orleans, LA , December 2022
21. Treating Adolescents and Young Adults (AYA) with Blood Cancer; LLS Webinar. October 11, 2023.
22. Leukemia and Lymphoma Society – Light the Night Walk. October 2024, Atlanta GA
23. American Cancer Society (ACS) - Hematologic Cancer Collaborative Partner. Invited 2024
24. Hodgkin Lymphoma – Highlights from the ASH 2024 Meeting: LRF Webinar. Feb. 5, 2025
25. Patient and Survivor Scholarship Reviews for Leukemia and Lymphoma Society, October 2024

b. **Media Appearances:**

1. UNC-TV Healthwise Series- Panel on Childhood Cancer, Chapel Hill, NC, 2006
2. Morning News Spot on Childhood Cancer Survivorship – WXIITV, 2006
3. WXII TV New -St. Baldrick's Research Award Recipient, 2013
4. WFMY II News - Hyundai Hope on Wheels Award Ceremony, Winston-Salem, NC September 2014
5. MDedge Roundtable- moderator: Advances in CD30- and PD-1-targeted therapies for classical Hodgkin Lymphoma, MDedge Hematology and Oncology, Record Feb. 4, 2021; Release March 2021 https://www.mdedge.com/hematology-oncology/advances-targeted-therapy-chl-roundtable
6. 11Alive News - https://www.11alive.com/article/news/local/outreach/brave-conquers-fear/woman-wants-become-nurse-after-battling-leukemia-teen. June4, 2021
7. Good Morning America. https://www.goodmorningamerica.com/GMA3/video/passion-purpose-cancer-survivor-nurse-81917173 Dec. 23,2021
8. The Hill- https://thehill.com/changing-america/well-being/longevity/3780911-medicaid-expansion-linked-with-improved-cancer-survival-in-young-adults/ Dec. 19, 2022
9. Kaiser Health News - https://khn.org/morning-breakout/omnibus-deal-would-delay-medicare-pay-cuts-move-up-medicaid-cutoffs/ December 20, 2022
10. American Journal of Managed Care - https://www.ajmc.com/view/what-we-re-reading-improved-cancer-survival-in-young-adults-pediatric-medicine-shortage-future-of-covid-19-vaccines December 20, 2022
11. Technology Networks - https://www.technologynetworks.com/cancer-research/news/medicaid-expansion-increases-cancer-survival-for-young-adults-study-finds-368617 December 20, 2022
12. Local Today - https://localtoday.news/wi/medicaid-expansion-associated-with-improved-cancer-survival-in-young-adults-2-57380.html 2024 December 20, 2022
13. Health - https://consumer.healthday.com/obamacare-2658988530.html Dec 27, 2022
14. US News and World Report - https://www.usnews.com/news/health-news/articles/2022-12-27/obamacare-may-have-helped-extend-lives-of-young-cancer-patients Dec. 27, 2022
15. For children with leukemia or lymphoma, what does a pediatrician need to know . https://www.contemporarypediatrics.com/view/for-children-with-leukemia-or-lymphoma-

what-does-a-pediatrician-need-to-know- Contemporary Pediatrics ;July 26.2023

16. Invited comment on "Progress in childhood cancer has stalled for Blacks and Hispanics" Progress in childhood cancer has stalled for Blacks and Hispanics, report says | AP News
17. COG Research leads to game-changing improvements for pediatric Hodgkin Lymphoma treatment. https://www.thecogfoundation.org/cog-research-leads-to-game-changing-improvements-for-pediatric-hodgkin-lymphoma-treatment.html 2023
18. The Leukemia & Lymphoma Society. Hematology Horizons Vlog Series. "Highlights in Blood Cancer Research." https://lls.org/patient-education-videos/hematology-horizons-vlog-series. December 18, 2024.
19. Parents of kids with cancer fear GOP budget cuts could slash Medicaid; April 25, 2025 (reporter Elizabeth Cohen)

c. **Social Media:**
   1. X - Sharon M. Castellino (@SharonCastelli2)
   2. The Bloodline with LLS: A podcast for patients and caregivers : Bridging the Gaps: Striving for Accessible Cancer Care - The Bloodline with LLS. Posted May 28, 2024

19. **Honors and Awards:**
   1. Dana Fellowship for Research, Mount Holyoke College, 1985
   2. Bernice Maclean Freshman Biology Award, Mt. Holyoke College, 1985
   3. Sara Williston Scholar, Mt. Holyoke College, 1986
   4. Louisa Stone Stevenson Award in Chemistry, Mt. Holyoke College, 1987
   5. Phi Beta Kappa, Mt. Holyoke College, 1988
   6. Sigma Xi, Mt. Holyoke College, 1988
   7. American Society of Chemists Award, Mt. Holyoke College, 1988
   8. Mary P. Dole Scholarship for the Study of Medicine, 1988
   9. North Carolina Board of Governor's Scholarship for Medicine, 1988-1992
   10. Association for Brain Tumor Research, Medical Student Summer Fellowship, 1991
   11. E.E. Owen Award for the Clinical Sciences, Duke University School of Medicine, 1992
   12. American Medical Women's Association Award, Duke University, 1992
   13. Alpha Omega Alpha, Duke University School of Medicine, 1992
   14. Society for Pediatric Research (SPR), elected 2008
   15. Castle Connolly Top Doctor, 2009-present
   16. Best Doctors in America database, 2011-2015
   17. Clinician Investigator Award, Wake Forest School of Medicine, 2013
   18. Best Doctors in Atlanta, 2015-present
   19. Atlanta Magazine Top Doctor, 2016-2021
   20. Outstanding Mentor (for mentorship of women and minorities), Winship Cancer Institute, Emory School of Medicine, 2018
   21. Distinguished Mentor Award, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University Department of Pediatrics, Atlanta, GA 2019
   22. Honoree, Researcher Appreciation Day, Emory School of Medicine, Atlanta, GA, Sept. 2020
   23. Clinician Science Research Award, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University Department of Pediatrics, Atlanta, GA 2022
   24. Hal Simon Career Development Mentor Award, Emory SOM Dept. Pediatrics 2022
   25. Modern Luxury – The Atlantan Magazine Top Doctor, 2022-present

20. **Formal Teaching:**
   a. **Course Direction and Organization:**
      1. Medical Student Teaching

i. Clinical Correlation Lectures: Medical Students (MSI) Biochemistry, Medical Students, ETSU SOM, 1999-2004
   (a) Sickle Cell Disease, contact hours 1 hr./year
   (b) p53 and Li Fraumeni Syndrome, contact hours 1 hr./year
ii. Core Pediatric Clerkship Lectures Hematology/Oncology Topics, MSIII, ETSU SOM, 1998-2004, 6-8 contact hrs./year
iii. Oral exams administrator, MSIII, ETSU SOM, 1999-2004 contact hours: 4/yr.

b. **Institutional Lecture Duties Within the Setting of a Course or Rotations:**
   1. Residency Programs
      i. Core Residency Lectures: Oncologic Emergencies, Anemias, Abdominal Mass, Lymphadenopathy, ETSU Pediatric Residency, 1998-2004, contact hours 3-4/yr.
      ii. Core Residency Lecture: Bleeding Disorders, ETSU Internal Medicine Residency, 2000-2004, contact hours 1/yr.
      iii. Oncologic Emergencies, Transfusion Basics, Late Effects/Survivorship, Research methods (Reviewing for journals) Core Residency Lectures, Wake Forest SOM, 2005-2015, contact hours 5/yr.
   2. Fellowship Program
      i. Core Fellowship Orientation lecture: Oncologic Emergencies, Chemotherapy drugs. Aflac Cancer and Blood Disorders Center, Atlanta GA July 2018, 2019, 2020, 2021 contact hours 1.5/yr.
      ii. Diversity, Equity, and Inclusion Discussion Series: Healthcare Disparities in Pediatric Hematology/Oncology (Co-presenters: Staci Arnold, MD, MBA, MPH; Naadira Upshaw, PsyD), Aflac Cancer and Blood Disorders Center, Atlanta, GA, December 2020, contact hours 1/yr.
   3. Master's and PhD Programs
      i. Foundations of Translational Science Course – Fall 2009, contact hours 6/yr
      ii. Research methods in Survivorship, Masters in Health Outcomes 2011, contact hours 2/yr.
      iii. Core Curriculum lecture on Pediatric Cancer Survivorship- T32 (Post-doctoral) Training Grant Cancer Survivorship (PI Avis), 2013-2015, contact hours 2/year
      iv. Leukemia Lymphoma (Advance Practice Provider - APP) series: Acute Myeloid Leukemia; Hodgkin Lymphoma – workup and clinical approaches; Children's Healthcare of Atlanta, Atlanta GA, June 2016, 2018, contact hours 4 hrs./yr

c. **Small Group and Multi-Disciplinary Teaching:**
   i. Standardized Patient Assessment, Medical Students, Wake Forest SOM, 2007-2009, contact hours 8/year
   ii. Bedside Teaching Course, Medical Students, Wake Forest SOM, 2012-2014, Contact hours 18/year

d. **Other Categories:**
   1. Educational Podcast, The Bloodline with LLS: Health Equity in Blood Cancer Patients, Leukemia and Lymphoma Society, 1 contact hour, May 2024

21. **Supervisory Teaching:**
   a. **Bedside Teaching/Clinic Precepting:**
      1. Inpatient attending service for pediatric Hematology and Oncology (ETSU 1998-2004; Wake Forest School of Medicine 2004-2015; Emory University School of Medicine 2015-present)

b. **Mentoring Activities:**

Postdoctoral or Clinical Fellows

Name	Year(s) supervised	Current position and employer
Chandylen Nightingale, PhD, MPH	2014-2015	Assistant Professor, Social Sciences and Health Policy, Wake Forest SOM, Winston-Salem, NC
Lane Miller, MD, MSc	2017-2019	Private Practice, Children's Minnesota Cancer and Blood Disorders Center
Michael White, MD, MSc	2017-2019	Assistant Professor Aflac Cancer and Blood Disorders Center, Emory School of Medicine
Anthony Ross, MD	2018-2021	Assistant Professor, Indiana School of Medicine, IN
Holly Edington, MD , MSc	2019-2021	Private Practice, St. Jude Affiliate Clinic, Presbyterian Hospital, Charlotte NC
Julie Gilbert, MD	2020-2021	Pediatric Specialist, Inova Fairfax Hospital, Fairfax, VA
Pratik Patel, MD	2020-2021	Assistant Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA
Dailia Francis, MD, PhD	2021- present	Instructor, Department of Pediatrics, Emory University School of Medicine Pediatric Hematologist/Oncologist, Children's Healthcare of Atlanta, Atlanta, GA
Tarun Jain, MD, MSc	2022- present	Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Emory School of Medicine, Atlanta GA
Alexandra Cathcart, MD	2022-present	Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Emory School of Medicine, Atlanta GA
Jason Stevenson, MD	2023-present	Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Emory School of Medicine, Atlanta GA
Josh Muniz, MD	2024-present	Fellow, Pediatric Hematology/Oncology, Aflac Cancer and Blood Disorders Center, Emory School of Medicine, Atlanta GA

Residents

Name	Year(s) supervised	Current position and employer
Carmen Arkansas Nations, MD	1999-2002	Pediatrics, Cherokee Pediatrics, Cherokee, NC
Dawn Tuell, MD	2002-2004	Associate Professor and Residency Program Director, Pediatrics, East Tennessee School of Medicine
Michelle Taylor, MD	2003-2004	Deputy Director, Practice Integration at National Association of Community Health Centers, Bethesda, MD
Ashley Barber Xu, MD	2006-2010	Private Practice, General Pediatrics, Northwest Pediatrics Inc. Greensboro, NC
Megan Landsdale Holden, MD	2008-2009	Assistant Clinical Professor, Dept. Anesthesia, UCSF

Garrick Hill, MD,	2008	Assistant Professor Pediatric Cardiology, Medical College of Wisconsin
Nameeta Penkar Richard, MD	2010-present	Private Practice Pediatric Hematology/Oncology Portland, OR
Lee Heeringa, MD	2014-2015	Pediatricts, Trinity Health Medical Group, Grand Rapids, MI
Jason Stevenson, MD	2020-present	Fellow, Pediatric Hematology/Oncology, Atlanta GA
Taslima Choudhury, MD	2020	Fellow Pediatric Hematology/Oncology, Cincinnati, OH

Medical Students

Name	**Year(s) supervised**	**Current position and employer**
Zane Chiad	2014	Hematology/Oncology, Atrium Health Levine Cancer Institute, Concord, NC
Caroline Keenum-Walsh, MD	2016-2018	Resident, Emory School of Medicine, Department of Pediatrics (deceased 2022)
Zachary West, MD	2019-2020	Resident, Emory School of Medicine, Department of Pediatrics
Cortland Coxhead, MD	2021	Resident, Emory School of Medicine, Dept. Pediatrics
Kyle Grimes, MD	2013-2014	Pediatric Resident Military, Norfolk VA

Graduate Students (includes master's and doctoral students)

Name	**Year(s) supervised**	**Current position and employer**
Brooke Cherven RN, BSN, MPH, PhD	2018-2020	Assistant Professor, Aflac Cancer and Blood Disorders Center, Atlanta GA
Oluwafunbi Awoniyi, MD, MPH, MSc	2021	Internal Medicine Resident Physician, HCA Florida Healthcare

Allied Health Students (e.g., physician assistants, physical therapy students, etc.)

Name	**Year(s) supervised**	**Current position and employer**
Ashley Wester, PharmD	2014-2015	Wake Forest Baptist Medical Center, Winston-Salem, NC
Ann Schweppe, PA	2008-2011	PA WFUBMC, Pediatric Oncology, Winston-Salem, NC
Rachel Weaver, PA	2011-2013	Masters in Health Outcomes Program, Research Assistant, the Vanderbilt Center for Tobacco, Addictions and Lifestyle, Nashville, TN
Kat Pearsall, PA	2012-2014	WFU Pediatric Survivorship Clinic, Winston-Salem, NC

Undergraduate Students

Name	**Year(s) supervised**	**Current position and employer**

Emily Silverman, BSc	2018-2019	NYU School of Medicine – Class of 2024
Vivek Joshi	2021-2022	MPH Candidate Rollins School of Public Health

Other (e.g., Visiting Scholars, Junior Faculty)

Name	Year(s) supervised	Current position and employer
Anibal Borges Martinez, MD	2007-2009	Faculty Rose Family Medicine, Denver, CO
Karen Effinger	2013-present	Assistant Professor, Pediatrics, Emory School of Medicine
Melinda Pauly, MD	2015-present	Associate Professor, Pediatric Oncology, Emory SOM
Himalee Sabnis, MD, MSc	2015-present	Associate Professor, Pediatric Oncology, Emory SOM
Shogo Kobayashi MD, Visiting Professor Aflac Cancer and Blood Disorders Center Visiting scholar; Emory SOM, Atlanta GA	2016-2017	Assistant Professor Pediatric Oncology, Fukushima Medical University, Japan
Justine Kahn, MD, Candidate MS, Lymphoma Research Fellow	2016- present	Assistant Professor, NY-Presbyterian/Columbia University Medical Center
Tamara Miller, MD, MSc	2017- present	Associate Professor, Pediatric Oncology, Emory SOM (K07 mentorship team member)
Xu Ji, PhD	2019-present	Junior Faculty Aflac Cancer and Blood Disorders Center
Erika Freihling, (ASPHO mentoring for mid career faculty program)	2023-2024	Assistant Professor U. Pittsburgh School of Medicine
Mallorie Heneghan	2024- present	Assistant Professor University of Utah
Lauren Raney, MD	2023-present	Assistant Professor, Emory University
Diana Fridyland, MD	2024- presnt	Assistant Professor, Emory University

c. **Thesis or Dissertation Committees:**

Graduate Students

Name	Year(s)	Program	Institution
Sarah Rudolph	2006	MA: Dept of Communications	Wake Forest University, Winston Salem, NC
Caitlin Monroe	2015-2017	Masters in Public Health	George Washington University, Washington, DC
Lane Miller, MD, MSc	2017-2019	Masters in Health Outcomes	Emory School of Medicine
Holly Edington, MD, MSc	2019-2022	Masters in Health Outcomes	Emory School of Medicine
Tarun Jain, MD	2022-2024	Masters in Health Outcomes	Emory School of Medicine

Jennifer Geel	2024	PhD (Thesis reader)	University of the Witwatersrand, Johannesburg 2024
Joshua Muniz	2024-present	Masters in Health Outcomes	Emory School of Medicine

22. **Lectureships, Seminar Invitations, and Visiting Professorships:**
    a. **National and International:**
        1. "Interventions in Survivors of Cranial Radiation." Visiting Professor–Children's Hospital of Philadelphia PA; Host: Beverly Lange, MD. January 2009
        2. "Unveiling Modifiable Vascular Injury in Childhood Cancer Survivors" – Children's Hospital of Philadelphia; Host, Jill Ginsberg, MD. December 2010
        3. "Follow the Yellow Brick Road: Caring for your Brain and Heart after Cancer Therapy." Visiting Professor, Hawaiian Children's Cancer Foundation and Kapi'olani Medical Center for Women and Children. Honolulu, HI; Host: Diane Ono. September. 2013
        4. "Back and to the Future: Hodgkin Lymphoma- Lessons for Survivorship." Visiting Professor, Pediatric Grand Rounds, Kapi'olani Medical Center for Women and Children. Honolulu, HI. September. 2013
        5. "Hodgkin Lymphoma: Rear View mirrors; Blind Spots; Moving Forward." AFLAC Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA Feb. 2015
        6. "Rear View mirrors, Blind Spots and Moving Forward with targeted therapy for Hodgkin Lymphoma." Visiting Professor, U. Colorado School of Medicine, Denver, CO. Host: Doug Graham, MD, PhD. July 2015
        7. Evaluation of Activation of a national cancer institute national Clinical Trials Network (NCTN) Study, S1826, for Hodgkin Lymphoma (HL) at Children's Oncology group (COG) Institutions, (Virtual presentation to Cancer care Delivery Research Committee, COG), Host: Susan Parsons, MD, MRP, November 2020
        8. Closing the Survivorship Gap in Pediatric and Adolescent Hodgkin Lymphoma, Rutgers University Cancer Center Grand Rounds and visiting Professor, Newark, NJ, Host: Peter Cole, MD, PhD, November 2020
        9. Optimizing Enrollment on National cancer Trials Network (NCTN) Adolescent and Young Adult (AYA) trials- The Children's Oncology Group Experience. (Co-presenter with Mike Roth, MD, Aaron Weiss, DO, Furqan Shaik MD) Virtual meeting, National Cancer Trials Network monthly meeting. December 2020
        10. The Feedback loop from Survivorship to Targeted care: Novel Paradigms in Pediatric and AYA Hodgkin Lymphoma, Roswell Park cancer Center, Population Sciences program. Buffalo, NY. Host Kara Kelly MD, October 2021 (virtual)
        11. Evolution of Targeted Therapy in Pediatric and Adolescent Hodgkin Lymphoma (HL)- Beginning with the end in mind. Duke University, Department of Pediatric Grand Rounds- honored alumni speaker. Durham, NC. Host Robert Drucker, MD. November 2021 (virtual)
        12. ASPHO Webinar Series- Overcoming Obstacles to Advancement for Women in Medicine- Pediatric Hematology/Oncology Perspectives (Co_presenter with Drs. Diane Nugent and Ify Osunkwo; Moderators Drs. Carolyn Bennett and Adit Tal). Dec. 8, 2021
        13. Organ Health after childhood cancer III- Hepatic Late Effects. St. Jude-VIVA Foundation Childhood Cancer Survivorship Care Overview Webinar Programme. Host Jennifer Yeo and Melissa M Hudson, MD. February 25, 2022 (virtual)
        14. Childhood, Adolescent and Young Adult (AYA) Hodgkin Lymphoma -Closing the Survivorship Gap-Beginning with the End in Mind. Pediatric Grand Rounds, Golisano Children's Hospital, University of Rochester School of Medicine, Rochester NY February 17, 2023 Host: Jonathan Friedberg, MD

15. Treating Adolescents and Young Adults (AYA) with Blood Cancer – (Co-presenter with Dr Julie Wolfson). October 11, 2023. https://www.lls.org/professional-education-webcasts/treating-adolescents-and-young-adults-aya-blood-cancer
16. Optimizing survival in child and adolescent cancer – from retrospective cohorts to clinical trials. University of Florida Cancer Center Survivorship Symposium. Nov. 8, 2023, Jacksonville, FL (host: Ray Maihoit-Vega, MD, MPH)
17. Moving the needle or threading the needle: Advances in Pediatric and AYA Hodgkin Lymphoma. MSK Kids, Nov. 30,2023, New York New York.Vu
18. Medi: ASH 2023 Insights: S1826 Trial Nivo-AVD compared to Brentuximab vedotin-AVD in pediatric advances stage cHL. December 21, 2023
19. Are we there yet? Advances in Pediatric and AYA Hodgkin Lymphoma. UPMC Pediatric Grand Rounds. Feb. 22, 2024
20. Beyond Owl Eyes – Advances in Pediatric and AYA Hodgkin Lymphoma. Science of Childhood Cancer Series, St. Jude Children's Research Hospital Virtual Forum: Feb. 29, 2024
21. St.Jude-VIVA Survivorship – Childhood Cancer Survivorship Care Webinar Series: Hodgkin Lymphoma – The Past and Future of Survivorship. May 17, 2024 (749 registrations from 54 countries)
22. Progress through Collaboration- Lessons from S1826. Chicago May 2024
23. COG Young Investigator Symposium- Breakout Session - Collaboration outside COG: Adult Cooperative Groups Webinar May 2, 2024
24. LRF Workshop on Survivorship- virtual meeting: Importance of Measurements in Survivorship Research for Patients Treated with Novel Therapies – January 2025 (Host: Lindsay Morton, PhD)
25. Advancing care for Hodgkin Lymphoma – Novel Therapy and Collaborations– University of Alabama- Pediatric Oncology Grand Rounds. Birmingham AB January 13, 2025
26. NY vSymPHOny. Advances in Hodgkin Lymphoma; Virtual Presentation March 24, 2025
27. Medicaid Under Pressure: Supporting Families Through Policy Change. Advoccy Webinar, Pediatric Brain Tumor Foundation; Virtual Presentation. July 30, 2025 (244 registrants)

a. **Regional:**
1. Office Approach to Anemia. 15th Annual South West Virginia Pediatric Conference, Abingdon, VA. July 1999.
2. "Clots in Tots." Pediatric Grand Rounds, Wellmont Medical Center, Kingsport TN, Feb 2002
3. "Hepatitis C in Childhood Cancer survivors." Annual St. Jude Affiliate Physician Conference Memphis, TN, Oct. 2002
4. "Chronic Hepatitis C Infection in Survivors of Childhood Cancer – An Update of the St. Jude Children's Research Hospital (SJCRH) Hepatitis C Seropositive Cohort." UT Memphis – Division of GI Seminar, Oct 2, 2003
5. "Cognitive Dysfunction after childhood Cancer." Cognition and Cancer: Broadening the Dialogue, Winston-Salem, NC, March 2009
6. "Surviving Childhood Cancer – Partnership in Health." Winston-Salem Health Care, Winston-Salem, NC. May 2011
7. "Optimizing Health During and after Cancer Survivorship", Wake Forest Comprehensive Cancer Center. Workshop of Adolescent and Young Adult Cancer Survivors. Winston Salem, NC. Sept. 2016
8. "Hodgkin's Lymphoma: advancing therapy and improving outcomes beyond cancer free survival -Beginning with the End in Mind." Pediatric Grand Rounds. Children's Healthcare of Atlanta, Emory University School of Medicine, 11-16-2022
9. Advances in Biology and Therapeutics. UGA-Winship Cancer Center Summit, Athens GA, April 21, 2025

b. **Institutional:**

1. "Spongioform Encephalopathies." Pediatric Grand Rounds. ETSU SOM, Johnson City Medical Center, 1999.
2. "Cytopenias in children." Pediatric Grand Rounds. ETSU SOM, Johnson City Medical Center, 2000.
3. "Chemotherapy Basics" Oncology Nursing Core, Johnson City Medical Center, Johnson City TN 2000.
4. "Pediatric Solid Tumors." MHSA Oncology Nurses Core, Johnson City Medical Center 2000
5. "Thrombosis in Children." Pediatric Grand Rounds. ETSU SOM, Johnson City Medical Center, 2001.
6. "ITP and Evan's Syndrome." Practicing Medicine Grand Rounds, ETSU SOM, 2002
7. "Epidemiology of Chronic Hepatitis C in Survivors of Childhood Cancer." Pediatric Grand Rounds. ETSU SOM, Johnson City Medical Center, 2003.
8. "The Cost of Cure: Surviving Childhood Cancer." Pediatric Grand Rounds, Wake Forest SOM, Winston-Salem, NC, 2006.
9. Neonatal Alloimmune Thrombocytopenia, Wake Forest University Pediatrics Morning Report Winston-Salem, NC 2006
10. "Surviving Childhood Cancer: Successes and Challenges for the Adult Provider." Medical Oncology Grand Rounds, WFU Comprehensive Cancer Center. March 2008.
11. Life after cancer- Cases from the AWAKE Clinic, Wake Forest Medical Center Pediatric Grand Rounds, Winston-Salem, NC, Sept. 2011
12. Life after cancer- Endocrine Late Effects, Wake Forest Medical Center Endocrinology Grand Rounds. Winston-Salem, NC, February 2012
13. "Unveiling modifiable Cardiovascular Injury in Childhood Cancer Survivors." Epidemiology Seminar, WFU SOM. March 2012.
14. Childhood and AYA Cancer Survivorship – Bridging Clinical Care and the Science of Late Effects, Survivorship Post-doc seminar, Wake Forest Comprehensive Cancer Center, April 2015
15. Hodgkin Lymphoma – New Paradigms toward Improving outcomes. Aflac ARC Conference, Emory University School of Medicine. Atlanta GA1 hour/yr. June 2018
16. Pediatric and AYA Hodgkin Lymphoma – Novel Therapeutics, Endpoints and Outcomes. Advances in Research, Aflac Cancer and Blood Disorders Center, CHOA; Emory University School of Medicine. Atlanta GA, November 2020
17. Leukemia and Lymphoma Program – Growth and Highlights – Annual faculty Retreat, Aflac Cancer and Blood Disorders Center, CHOA, Atlanta GA. Oct. 2020
18. ASCO Highlights: Brentuximab vedotin Demonstrates Superior EFS in Pediatric High-Risk Hodgkin Lymphoma, Aflac Cancer and Blood Disorders Center, CHOA, Atlanta GA. July 2022
19. Hodgkin's Lymphoma: advancing therapy and improving outcomes beyond cancer free survival -Beginning with the End in Mind. Pediatric Grand Rounds, Egleston Children's Hospital, Atlanta GA (virtual) Nov. 16, 2022
20. Hodgkin Lymphoma: Practice changing trials and unanswered questions. Advances in Research, Aflac Cancer and Blood Disorders Center, CHOA; Emory University School of Medicine. Atlanta GA, February 2025

2. **Invitations to National/International, Regional, and Institutional Conferences:**

a. **National and International:**

1. "Single Institution Experience with COG type Neuropsychological Battery." Children's Oncology Group (COG) Meeting Symposium on Cognitive Dysfunction, Dallas, TX, Sept.

2009

2. “Acetylcholinesterase Inhibitors in Survivors of Cranial Radiation.” COG Meeting Symposium on Cognitive Dysfunction, Dallas, TX, Sept. 2009.
3. “Pilot Study of Donepezil in Pediatric Brain Tumor Survivors after Cranial Radiation Therapy.” COG Meeting Symposium on Cognitive Dysfunction, Dallas, TX, Sept. 2009.
4. “Marking your Career Path, COG Young Investigator Committee -Symposium Speaker. COG Spring Meeting. Los Angeles, CA, March 23-26, 2010
5. “Disparities Among ASPC: Evidence from the Childhood Cancer Survivor Study.” GW Cancer Institute Biennial Cancer Survivorship Research Symposium. Washington, DC. May 2011.
6. “AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents.” (Study Design, Progress, and Updates to entire COG participant groups, in my role as Study Chair) COG Meetings, each Spring and Fall: Minneapolis, MN April 9-12, 2013; Dallas, TX October 7-11, 2013; St. Louis, MO April 1-4, 2014; Dallas, TX September 1-19, 2014; Atlanta GA April14-17,2015; Dallas TX October 6-9 2015; St. Louis MO March 8-11, 2016; Atlanta GA September 13-16, 2016; St. Louis, MO March 28-30, 2017; Atlanta GA (virtual- ice storm) September 12-15, 2017; St. Louis MO April10-13, 2018; Dallas TX October 2-5, 2018; Denver CO March 12-15, 2019; Atlanta GA September 10-13,2019; Chicago IL (virtual due to COVID19 pandemic) March 17-20, 2020; April 2021 (virtual) l October 2021 (virtual), March 2022 (virtual)
7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. MOC Part 2-Learning Session at The American Society of Pediatric Hematology/Oncology 29th Annual Meeting, May 11-14, 2016, Minneapolis, MN
8. Planning for an Intergroup trial (S1826) in advanced stage Hodgkin lymphoma. Children’s Oncology Group, Spring Meeting 2018, St. Louis, MO
9. Novel Therapeutics, Endpoints and Outcomes in Hodgkin Lymphoma. Best of COG, American Society of Pediatric Hematology/Oncology Annual meeting, May 2-5, 2018, Pittsburgh, PA
10. Immune Modulation in Pediatric Lymphoma. Poster Discussant. American Society of Clinical Oncology Annual Meeting, June 1-5, 2018, Chicago, IL
11. Proof- of paradigm of Cost Effectiveness Analysis within a Therapeutic Clinical Trial. Education Session. (co-speaker with S Parsons and R Yarbroff). American Society of Clinical Oncology Annual meeting- Education Session, June 1-5, 2018, Chicago, IL
12. Scientific Chair’s Report Hodgkin Lymphoma Committee to COG membership body– March 2022 (virtual update; prerecorded).
13. ASCO Highlights: Brentuximab vedotin Demonstrates Superior EFS in Pediatric High-Risk Hodgkin Lymphoma, Children’s Oncology Group. General Session Fall Meeting; New Orleans, LA October 2022
14. Medical Crossfire: Maximizing our clinical practices in Hodgkin Lymphoma:Treating Pediatric Patients with Hodgkin Lymphoma-Differences and Similarities with Adult Patients. American Society of Hematology Satellite Symposium, December 9, 2022, New Orleans, LA
15. Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship. Dec, 20, 2022, Virtual CME, (sponsored by Global Education Group, PlatformQ Health Education, LLC, National Organization for Rare Disorders (NORD) (virtual CME)
16. Euronet Meeting. Paris,France January 2023
17. Novel Therapeutics in Children and AYA with classic Hodgkin Lymphoma. ASPHO May 11, 2023, Parkland TX
18. ASCO Highlights: S1826: “A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly

Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Children's Oncology Group. General Session Fall Meeting; Atlanta GA October 2023

19. State of the art in management of Hodgkin Lymphoma (HL) in children and adolescents. LXIV Congresso Nacional de Hematologia. October 26, 2023 Merida, Mexico
20. ASCO Educational Session: (Chair) Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision making. Chicago IL, June 3, 2024
21. "Pediatric/AYA Biomedical & Health Equity Research: The Importance & Intersection" Panel Discussion. The Leukemia & Lymphoma Society, Dare to Dream Forum. Chicago, IL, September 20, 2024
22. International Society for Hodgkin Lymphoma (ISHL13) -Overview of Advances in Treatment of Hodgkin Lymphoma for Children, Adolescents, and Young Adults, October 23, 2024, Cologne Germany.
23. Importance of Measurements in Survivorship Research for Patients Treated with Novel Therapies. The Lymphoma Research Foundation Virtual Survivorship Workshop. January 10, 2025
24. Lymphoma Research Foundation-AYA Symposium: Engagement of Survivors – the LEAP study. Jersey City NJ 2025 (Host: Kara Kelly, MD and Andy Evens DO)
25. Advances in Hodgkin Lymphoma. ASPHO Annual Meeting, Louisville KY; May 10, 20225,

b. **Regional:**

1. "Office Approach to Anemia." 15th Annual South West Virginia Pediatric Conference, Abingdon, VA. July 1999.
2. "Pilot Study of Donepezil in Pediatric Brain Tumor Survivors after Cranial Radiation Therapy." North Carolina Pediatric Hematology/Oncology Consortium, Chapel Hill, NC. Feb. 2007.
3. "Surviving Childhood Cancer: What the Future Holds." Practical Pediatrics, Winston-Salem, NC. April 2011.
4. "Life After Cancer – Cases from the Clinic." 27th Annual Southwest Virginia Pediatric Conference, ETSU SOM, Abingdon, VA. August 2011.
5. "The Resonance Imaging Trial of Heart bioMarkers." North Carolina Pediatric Hematology/Oncology Consortium, Greensboro, NC. Feb. 2013.
6. "AWAKE- Healthy Survivorship." WFUCCC AYA Survivor Conference. Winston-Salem, NC. April 2014
7. ASCO Highlights: Brentuximab vedotin Demonstrates Superior EFS in Pediatric High-Risk Hodgkin Lymphoma, Winship Cancer Center Town Hall- Research Advances- Highlights. Emory School of Medicine (virtual) March 14, 2023

c. **Institutional:**

1. "Pilot Study of Donepezil in Pediatric Brain Tumor Survivors after Cranial Radiation Therapy." Annual Brain Tumor Center of Excellence Retreat. WFU Comprehensive Cancer Center. Sept. 2009
2. "Unveiling Cardiovascular and Cerebrovascular Injury In Childhood Brain Tumor (BT) Survivors." Annual Brain Tumor Center of Excellence Retreat. WFU Comprehensive Cancer Center. Sept. 2014
3. "Surviving Childhood Cancer – Not for the faint of heart." Wake Forest Hypertension and Vascular Research Center, Annual Red Dress Day Seminar, Winston-Salem, NC, Feb 2015
4. Epidemiology to Outcomes and Moving Forward in Clinical Trials in Children and AYA: Faculty Meeting. Aflac Cancer and Blood Disorders Center, March 27, 2023

3. **Abstract Presentations at National/International, Regional, and Institutional Conferences:**

a. **National and International:**

1. ***Castellino, S,** Hudson MM. Hepatitis C Infection in Survivors of Childhood Cancer. Pediatric Academic Societies' Annual Meeting, Seattle Washington, May3-6, 2003 (oral)
2. ***Castellino, S,** Hudson MM. The Epidemiology Hepatitis C Infection in Childhood Cancer Survivors. 54 th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA Oct 26, 2003 (oral)
3. ***Castellino S**, Hudson MM, Mertens A, Yeazel M, Whitton J, Brooks S, Ablin A, Castleberry RP, Hobbie WL, Kaste S, Robison L, Oeffinger K. Comparison of long- term outcomes, health care utilization, and health behaviors in young adult African American (AA) survivors of childhood cancer with White, Non-Hispanic (WNH) survivors: A childhood cancer survivor study (CCSS). 2004 APS/ASPHO Mtg, San Francisco, CA. (poster)
4. *Lansdale M, Marina N, **Castellino S**, Goodman P, Hudson MM, Mertens AC, Sklar CA, Leisenring W, Robison LL, Oeffinger KC. Screening for hepatitis C virus (HCV) in long-term pediatric cancer survivors- A report from the childhood cancer survivor study (CCSS). Cancer Survivorship: Embracing the Future October 4–6, 2006, Bethesda, MD. (poster)
5. *Cohen D, Flowers L, Parsons S, Kim J-Y, McMullen K, Shaw E, **Castellino S**. Pilot Study of Donepezil in pediatric Brain Tumor Survivors after Cranial Irradiation: Effects on Quality of Life and Cognitive Function. American Society of Pediatric Oncology Nurses. Milwaukee, October 2007 (poster)
6. ***Castellino SM**, Shaw E, Cohen D, Flowers L, McMullen K, Tooze J, Parsons S. A pilot study of Donepezil in pediatric brain tumor survivors who received cranial irradiation. Annual Meeting American Association of Cancer Research (AACR), April 2008 (poster)
7. *Anderson P, Hughes D, Odom LF, **Castellino S**, Torno L, Vyas YM, Yeager N, Shen V, Homans A, Gonzales C, Kuerbitz S, Kleinerman E. L-MTP-PE Compassionate Access and Aerosol GM-CSF Therapy for Osteosarcoma. ASPHO, May 7, 2008 (Cincinnati, OH) (poster)
8. ***Castellino SM**, Tooze, J, Geiger A, Leisenring W, Goodman P, Mertens A, Stovall M, Robison L, Hudson M. Risks of Mortality in 5-year survivors of Hodgkin's Lymphomas in the Childhood Cancer Survivor Study (CCSS). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL (May 31,2008) (oral)
9. ***Castellino SM**, Tooze JA, McMullen K, Hilderbrand B, Tegler C. Cerebral Hemodynamics in Pediatric Brain Tumor Survivors receiving Donepezil. Late Effects in Childhood Cancer Survivors, Williamsburg, VA (June 2010) (also presented at Children's Oncology Group Young Investigator symposium, October 2010, Los Angeles CA) (poster)
10. ***Castellino SM**, Tooze JA, D'Agostino Jr. R, Fareed SB, Lane K, Hamilton CA, Geiger AM, Hundley WG. Evaluating an Imaging Biomarker of Cardiovascular
11. disease in childhood cancer survivors: A Pilot Study. American Society for Preventive Oncology, Las Vegas, NV, March 2011 (poster)
12. ***Castellino SM**, Keller F, Dunphy C, McCarten K, Thomson J, Voss S, Nachman J, Constine L, Chen L, Schwartz C. Mixed cellularity (MC) histology confers favorable prognosis in Children and Adolescents with Low-Risk Hodgkin Lymphoma (HL). First International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma. Arlington, VA (May 12-14, 2011) (oral)
13. *Hudson M, Oeffinger K, Nathan P, Mertens A, **Castellino S**, Mulrooney D, Gurney J, Armstrong G, Leisenring W, Robison L, Ness K. Longitudinal changes in health status of the Childhood Cancer Survivor Study cohort. Pediatric Blood Cancer; 2011:57(5) epub online; 43rd Congress of the International Society of Pediatric Oncology (SIOP) 2011 Auckland, New Zealand, 28th–30th October 2011 (oral)
14. ***Castellino SM,** Tooze JA, Flowers L, Shaw E, Parsons SK. Benefits on Behavior and Health Related Quality of Life in Childhood Brain Tumor Survivors receiving Donepezil. Late Effects in Childhood Cancer Survivors, Williamsburg, VA (June 2012) (poster)
15. *Wilson CL, Leisenring WL, Oeffinger K, Nathan PC, Wasilewski-Masker K, Hudson MM,

Castellino, SM, Armstrong GT, Brinkman TM, Robison LL, Ness KK. Predictors of declining levels of physical activity among adult survivors of childhood cancer. Am Soc Clinical Oncology, Chicago, June 2013 (poster)

16. *Keller FG, Nachman J, **Castellino SM**, Constine LC, Voss S, Thomson J, Dunphy C, McCarten KM, Chen L, Schwartz CL. Very Early Response as measured by (18F) fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) After One Cycle of Chemotherapy in Newly Diagnosed Low Risk Hodgkin Lymphoma (HL). 9th International Symposium on Hodgkin Lymphoma. Cologne, Germany, 12th-15th October 2013 (oral)
17. ***Castellino SM** et. al. Outcomes and Patterns of Failure in Children/Adolescents with low-risk Hodgkin Lymphoma (HL) who are FDG-PET (PET3) positive after AVPC therap**y** International Symposium Pediatric HL. Berlin, May 2014. Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium. Berlin, Germany, May 7-10, 2014 (oral)
18. *Effinger K, Leisenring W, Oeffinger KC, Hudson MM, Ness KK, Marina N, **Castellino SM** Stovall M, Armstrong GT, Robison LL, Sainani K, Whittemore AS. Longitudinal Evaluation of Health Status in Aging Pediatric Hodgkin Lymphoma Survivors: Report from the Childhood Cancer Survivor Study. International Symposium Pediatric HL. Berlin, May 2014. Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium. Berlin, Germany, May 7-10, 2014 (oral)
19. *Keller F, **Castellino SM** et.al Intensive therapy free survival (ITFS) for early-stage Hodgkin lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy alone. Childhood, Adolescent and Young Adult Hodgkin Lymphoma, 2nd International Symposium. Berlin, Germany, May 7-10, 2014 (oral)
20. Williamson R, *SL Golden, AC Mertens, JA Tooze, N Avis, **Castellino SM**. Health- Related Quality of Life in Childhood Cancer Survivors at Risk for Cardiovascular Late Effects. Inaugural PROMIS Health Organization Conference, Philadelphia, PA, May 14, 2015 (poster)
21. *Williamson R, Mertens AC, Tooze JA, Golden SL, Avis N, **Castellino SM**. Physical and Mental health Function in Young Adult Survivors of Pediatric Cancer at risk for CV late effects following contemporary treatment. 14th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. Arlington, VA. June 11, 2015 (poster)
22. ***Castellino SM**, Tooze JA, Jordan J, Mertens AC, Golden SL, Williamson R, Stillman AE, Vasu, S, lane K, Hamilton CA, Hundley WG. “Evaluating the Utility of Cardiac Magnetic Resonance imaging in Childhood Cancer Survivors: The Resonance Imaging Trial of Heart Biomarkers (RITHM)” 14th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. Arlington, VA June 11, 2015 (poster)
23. *Pauly M, Lee B, Travers C, Lew G, Sabnis H, **Castellino SM.** Prescribed Doses of Maintenance Oral Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia Varies by Patient Race. The American Society of Pediatric Hematology/Oncology 29th Annual Meeting, May 11-14, 2016, Minneapolis, MN (poster)
24. ***Castellino SM**, Pleasant K, Keyes G, Poehling K, Tooze JA. A Population Based Study of Uptake of Human Papilloma Virus (HPV) Vaccine in Cancer Survivors. The American Society of Pediatric Hematology/Oncology 29th Annual Meeting, May 11- 14, 2016, Minneapolis, MN (poster)
25. *Effinger, KE, Broder WL, Record E, Mertens A, Rose-Felker K, **Castellino SM** and Meacham LR. A Cardio-Oncology Algorithm: Standardizing Referrals to and Recommendations from Cardiology in Childhood Cancer Survivors. The Fifth European Symposium on Late Complications after Childhood Cancer (ESLCCC16), Copenhagen, Denmark, 22 - 23 September 2016. (poster)
26. *Jordan J, Tooze JA, Golden SL, Stillman A, Hundley G, **Castellino SM**. Elevated

myocardial extracellular volume (ECV) occurs independently of LVEF declines in pediatric cancer survivors. Global Cardio-Oncology Summit. Vancouver CA. Sept. 28-30, 2016. (poster)

27. Kelly MJ, *Parsons SK, Cohen JT, **Castellino SM**, Kelly K, Keller F, Henzer TJ, Kumar A, Johnson P, Meyer RM, Morton LM, Tadford J, Raemaekers J, Hodgson DC, Evens AM. Construction of a Decision Model to aid treatment Choices For Early Stage Hodgkin Lymphoma: Bringing Survivorship Forward. 10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 22-25, 2016. (Poster)
28. ***Castellino SM**, Henderson TO, Keller FG, Kelly K, Curtis R, Conti RM, Parsons SK. Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III
29. Clinical Trial for Advanced Stage Classical Hodgkin in Children and Adolescents." 10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 22-25, 2016. (Poster)
30. *Henderson, TO, **Castellino*, SM**, Keller, FG, Kelly, K, Curtis, R, Conti, RM, Parsons, SK, Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin in Children and Adolescents. 58th Annual ASH Annual Meeting, San Diego, CA. Abstract 3583, 2016. (Poster)
31. *Henderson, TO, **Castellino* SM**, Keller, FG, Kelly, K, Curtis, R, Conti, RM, Parsons, SK, Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin in Children and Adolescents. 3rd International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL-3), Washington DC, May11-13, 2017. (Poster)
32. *Dave H, VanPelt S, Jenkins G, Horton TM, Alibhani A, Pei W, Keller F, **Castellino SM**, Kelly K, Bollard C. Feasibility of xMAP technology for detection of biomarkers in pediatric high-risk Hodgkin Lymphoma in the setting of a cooperative group Phase III clinical trial. 3rd International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL-3), Washington DC, May11-13, 2017. (Poster)
33. *Keenum C, Sabnis H, Williamson Lewis R, Patterson B, Effinger K, Bergsagel J, Mertens A, **Castellino SM**. Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, Atlanta GA. June15-17, 2017. (Poster)
34. ***Castellino S**, Belle-Isle L, Williamson Lewis R, Effinger K, Meacham L, Border W, Wasilewski-Masker K, Mertens A. Prevalence and Predictors of Pediatric cancer survivors Reporting Being Seen by a Cardiologist Following the Completion of therapy. 15th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, Atlanta GA. June15-17,2017. (Poster)
35. *Miller L, **Castellino SM**, Mertens A, Keller F, Woods W. Incidence and predictors of adverse respiratory events during induction therapy in children with acute myeloid leukemia. American Society of Hematology, Atlanta GA. Dec. 2017 (poster)
36. *Kahn J, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, **Castellino SM**. Survival by race/ethnicity in children and adolescents with Hodgkin lymphoma treated on cooperative group trials in the U.S. and Canada: A pooled analysis of Children's Oncology Group Trials. American Society of Hematology/Oncology, Atlanta GA. Dec. 2017 (oral presentation)
37. *Effinger KE, Keller F, Bergsagel J, Lawrence T, Lewis R, Meacham L, Mertens A, **Castellino SM**. Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Treated with Contemporary Therapy. American Society of Hematology, Atlanta GA. Dec. 2017 (poster)
38. *Sabnis H, Keenum C, Lewis R, Silverman E, Patterson B, Effinger K, Bergsagel J, Mertens A, **Castellino SM.** Growth disturbances in pediatric patients receiving long term tyrosine kinase inhibitor therapy. American Society of Hematology/Oncology, Atlanta GA. Dec. 2017

(poster)

39. *Kumar S, Travers CD, Bergsagel J, Keller FG, Pauly M, Sabnis H, **Castellino SM**, Lew G. Absence of Silent Inactivation Using Intravenous Pegasparaginase in Pediatric Acute Lymphoblastic Leukemia. American Society of Hematology/Oncology, Atlanta GA. Dec. 2017 (oral presentation)
40. *Effinger KE, Border WL, Rose-Felker K, Record E, Mertens AC, **Castellino SM**, Meacham LR. Working to Standardize Cardiology Care in Survivors of Childhood Cancer: A Pediatric Cardio-Oncology Score. American Society of Pediatric Hematology Oncology annual meeting, Pittsburgh, PA, May 2018 (poster)
41. *Kahn J, Kelly KM, Pei A, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, **Castellino SM**. Survival by age in children and adolescents with Hodgkin Lymphoma: A pooled analysis of Children's Oncology Group (COG) Trials. American Society of Clinical Oncology, Chicago IL. June 2018 (poster)(http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.7543)
42. *Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller F, Henderson TO, Bhatia S, Schwartz CL, **Castellino SM**. Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin Lymphoma; A pooled analysis of contemporary Children's Oncology Group trials. 11th International Symposium on Hodgkin Lymphoma, Cologne Germany, Oct. 27-29, 2018 (oral presentation, Kahn – Young Investigator award winner; **Castellino**, senior mentor)
43. Parsons SK, Kelly MJ, Cohen JT, **Castellino SM**, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer R, Radford J, Raemaekers J, Hodgson DC, *Evens AM. Early- Stage Hodgkin lymphoma (HL) in the modern era; harnessing Simulation Modeling to delineate Long-term patient outcomes. 11th International Symposium on Hodgkin Lymphoma, Cologne Germany, Oct. 27-29, 2018 (oral presentation, Evens)
44. *Rodday AM, Parsons SK, Bush R, Pei Q, Curtis R, Keller F, Kelly K, Henderson H, **Castellino SM**. Health related Quality of Life (HRQL) trajectories during treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL). 11th International Symposium on Hodgkin Lymphoma, Cologne Germany, Oct. 27-29, 2018 (poster)
45. *Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, **Castellino, SM**. Survival by age in children and adolescents with Hodgkin Lymphoma: A pooled analysis of Children's Oncology Group trials. 11th International Symposium on Hodgkin Lymphoma, Cologne Germany, Oct. 27-29, 2018 (poster)
46. *Cherven, B., **Castellino, S**., Chen, Y., Wong, F. L., York, J., Wasilewski-Masker, K., Hudson, M., Bhatia, S., Klosky, J. and Landier, W. (2018) Predictors of human papillomavirus (HPV) vaccine intent and subsequent initiation among adolescent and young adult cancer survivors. American Academy of Pediatrics National Conference and Exhibition, Orlando, FL, November 5, 2018 (poster)
47. *Parsons SK, **Castellino, SM**, Rodday AM, Keller F, Kelly K, Conti, R, Lerner D, Henderson TO. Productivity loss among parent caregivers is associated with poor health-related quality of life (HRQL) at the initial diagnosis of pediatric advanced stage Hodgkin Lymphoma (HL) ASH, San Diego CA Dec 1-4, 2018 (oral)
48. *Parsons SK, Rodday AM, Bush R, Pei Q, Curtis R, Waheed A, Keller F, Kelly K, Henderson T, **Castellino SM.** Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL) ASH, San Diego CA Dec 1-4, 2018 (poster)
49. *Sabnis HS, Lewis RW, Effinger KE, Allen K, Bergsagel J, Mertens A, **Castellino SM**. Gaps and opportunities in Surveillance for late Effects in pediatric patients receiving Tyrosine Kinase Inhibitor Therapy. North American Symposium on Late Complications After Childhood Cancer (NASLCCC), Atlanta, GA, June 20-22 (poster)
50. *Effinger KE, Allen K, Silverman E, Meacham L, Keller F, Lawrence T, Bergsagel J, Mertens

A, **Castellino SM**. Endocrine outcomes in Pediatric Hodgkin Lymphoma patients following modern therapy. North American Symposium on Late Complications After Childhood Cancer (NASLCCC), Atlanta, GA, June 20-22, 2019 (poster)

51. * **Castellino SM**, Rodday AM, Pei Q, Li M, Bush B, Keller F, Henderson TO, Kelly KM, Cella D, Parsons, SK. Performance of FACT-GOG-NTX to Assess Chemotherapy- Induced Peripheral Neuropathy (CIPN) in Pediatric Hodgkin Lymphoma (HL). ASCO, Chicago IL, May 31-June 4, 2019 (poster)
52. Sabnis HS, Mizukawa B, Glade-Bender J, Fangusaro J, Roberts S, Whitlow C, Winchester M, O'Brien M, Agresta L, Turpin B, Wechsler D, **Castellino S**, *Shukla N. Targeted Therapies for Children and Young Adults with Cancer: Single-Patient Use (SPU) Experience at Three Large Pediatric Cancer Programs. American Assoc. Cancer Research, Sept. 17-20, Montreal, QC, Canada (2019). (poster)
53. *Edington H, Chandrakasan S, Miller T, DeGroote N, Mertens A, **Castellino SM** . Immunoglobulin administration and hypogammaglobulinemia during pediatric acute leukemia therapy" accepted for poster presentation at the Association for Clinical and Translational Science (ACTS) Translational Science 2020 Conference Washington DC, April 14-17, 2020
54. *Summers RJ, Aumann W, Pauly M, Goldsmith K, Porter CC, Worsely R, Graham DK, **Castellino SM**, Wechsler DA. Next-Generation Sequencing Reveals Increased Prevalence of PICALM-MLLT10 Fusions in T-ALL and T-LLy. American Society of Pediatric Hematology/Oncology Annual meeting, Fort Worth TX May 6-9, 2020 (poster) (*meeting cancelled -COVID19 pandemic*)
55. *Wallace A, **Castellino SM**, Lewis RW, Effinger KE. Incident focal nodular hyperplasia (FNH) and Associated risk factors in Pediatric Cancer Survivors. American Society of Pediatric Hematology/Oncology Annual meeting, Fort Worth TX May 6-9, 2020 (poster) (*meeting cancelled -COVID19 pandemic*)
56. ***Castellino SM**, LeBlanc ML, Herrera AF, Parsons SK, Punnett A, Hodgson D, Rutherford SC, Khan N, Constine LS, Davison K, Prica AA, Friedberg JW, Kelly KM. An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. American Society of Clinical Oncology Annual Meeting Chicago IL, May 2020 (poster) (*virtual meeting -COVID19 pandemic*)
57. Smith SM, Sabnis HS, Lewis RW, Effinger K, Bergsagel J, Patterson B, Mertens A, Sakamoto KM, Schapira L, **Castellino SM**. Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors. American Society of Clinical Oncology Annual Meeting 2020 e22527(online publication)
58. *Summers RJ, Aumann W, Pauly M, Goldsmith K, Porter CC, Worsely R, Graham DK, **Castellino SM**, Wechsler DA. Next-Generation Sequencing Reveals Increased Prevalence of PICALM-MLLT10 Fusions in T-ALL and T-LLy. Annual Southeastern Pediatric Research Conference, Atlanta, GA Jun 12,2020 (poster) (*meeting cancelled -COVID19 pandemic*)
59. *Parekh A, Keller F, McCarten K, Kessel S, Pei Q, **Castellino S**, Constine L, Schwartz C, Hodgson D, Kelly K, Hoppe B. Impact of Early PET Response and Use of Radiotherapy on Patterns of Relapse in Early-Stage, Low-Risk Pediatric Hodgkin Lymphoma: Secondary Analysis of COG AHOD 0431. American Society of Radiation Oncology (ASTRO) October 25 - 28, 2020 Miami Beach, Florida *(Virtual meeting due to COVID)* (oral presentation)
60. Herrera AF, Li H, **Castellino SM**, Rutherford SC, Davison K, Evans AC, Punnett A, Constine LS, Hodgson DC, Parsons SK, Prica A, Kostakoglu L, Shipp MA, Laubach C, Leblanc M, Crump M, Kahl BS, Leonard JP, Kelly KM, Smith SM, Friedberg JW. SWOG S1826: A Phase III Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (poster)
61. Dave H, Mai M, Datar A, Jenkins G, Pei Q, Wu Y, Keller FG, **Castellino SM**, Horton TM,

Bollard CM. Increased tumor specific cytotoxic T cell responses and reversion to a favorable cytokine profile after treatment in patients with newly diagnosed high risk Hodgkin lymphoma treated on Children's Oncology Group Trial – AHOD1331. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (oral)

62. Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, **Castellino SM**, Franklin A, Keller FG, Shukla N. Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (poster)
63. Thomas BE, Perumalla P, Bhasin SS, Sarkar D, Dwivedi B, Park SI, DeRyckere D, Henry CJ, Raikar SS, Porter CC, Pauly M, Summers RJ, **Castellino SM**, Wechsler DS, Graham DK, Bhasin M. Single cell transcriptomics Revealed AML and non-AML cell clusters relevant to relapse and remission in Pediatric AML. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (oral)
64. Patel PA, DeGroote N, Esbenshade A, Cash WT, **Castellino SM**, Jaggi P, Miller TP. Infectious Outcomes of Pediatric Acute Lymphoblastic Leukemia Patients Presenting with Non-Neutropenic Fever. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8, 2020 (poster)
65. **Castellino SM**, Punnett A, Parsons SK, DeGroote N, Muehle S, Li H, Roth M, Herrera AF, Friedberg JW, Seibel N, Kelly KM. Evaluation of Activation of a NCI national Clinical trials Network Study S1826 for Hodgkin Lymphoma at COG Institutions. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (poster)
66. Kahn JM, Kelly KM, Pei Q, Wu Y, Friedman D, Henderson TO, Hodgson D, Kaplan J, Keller FG, Bhatia S, Schwartz CL, **Castellino SM**. Survival varies by age and histology in classical Hodgkin lymphoma: A report from the Children's Oncology Group. 62nd ASH Annual Meeting, *Virtual* Dec. 5-8,2020 (poster)
67. Edington H, DeGroote N, Miller T, Stevenson J, Chandrakasan S, Mertens A, **Castellino S**. Predictors and Outcomes of Immunoglobulin Supplementation in B-Cell Acute Lymphoblastic Leukemia. ASPHO Annual Meeting, Virtual April 20-23, 2021 Early *Career Award Recipient* (poster)
68. Stevenson J, DeGroote N, Choudhury T, Keller F, Brock K, Bergsagel DJ, Miller T, Cornwell P, Chonat S, **Castellino S**. Characteristics and Outcomes of Pediatric Oncology Patients at Risk for Transfusion Refusal. ASPHO Annual Meeting, Virtual April 20-23, 2021 (poster)
69. Ebelhar J, DeGroote N, Labudde E, McCauley Massie A, Allen K, **Castellino S**, Wasilewski-Masker K, Brock K. Differences in Palliative Opportunities across Diagnosis Groups in Children with Cancer. ASPHO Annual Meeting, Virtual April 20-23, 2021 (poster)
70. Miller TP, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Weisnicht A, Hsiao H, Bernhardt MB, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey LB. Comparison of Severe Toxicities Following High Dose Methotrexate Administration By Demographics and over Time in Pediatric Patients with Acute Lymphoblastic Leukemia. American Society of Hematology (ASH) Annual Meeting and Exposition, December 10-14, 2021. Atlanta, GA (poster).
71. Taylor ZL, Miller TP, DeGroote NP, Pommert L, Awoniyi O, Board SG, Poweleit EA, Kastner S, Ugboh N, Joshi V, Ambrosino N, Weisnicht A, Hsiao H, Bernhardt MB, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey LB. Influence of Albumin and Methotrexate Clearance on High-Dose Methotrexate-Induced Mucositis. 2022 ASCO Annual Meeting, June 3-7, 2022. Chicago, IL (poster).
72. Ji X, Hu X, Lipscomb J, Mertens A, **Castellino SM**. Utilization of Cardiac Surveillance in in Pediatric Blood Cancer Survivors Who Received Anthracycline-Based Therapy differs by Age: A claims-based analysis. American Society of Hematology, December 2021, Atlanta GA (oral)
73. Ji X, Shi K, Mertens AC, Zhao J, Yabroff KR, **Castellino SM**, Han X. Association between Medicaid expansion and Survival in Young adults with Cancer. American Society of Clinical

Oncology (ASCO), Chicago, June 3, 2022 (oral)

74. Ji X, Hu X,* Lewis R, Monroe C, Lipscomb J, **Castellino S**, Mertens A. "Association between Continuous Medicaid Coverage and Survival among Children with Cancer." (Poster) Presentation at the 11th Annual Southeastern Pediatric Research Conference. Atlanta, Georgia. June 3, 2022. (poster)
75. Ji X, Hu X, Lipscomb J, Mertens A, **Castellino S**. "Utilization of Cardiac Surveillance Tests in Anthracycline-treated Survivors of Pediatric Cancer." International Symposium on Late Complications after Childhood Cancer (ISLCCC), Utrecht, Netherlands. July 8-9, 2022.(poster)
76. ***Castellino SM**, Pei A, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett, Dave H, Henderson TO, Hoppe BS, Charpentier AN, Keller FG, Kelly KM. Brentuximab vedotin Demonstrates Superior Event Free Survival in Pediatric High-Risk Hodgkin Lymphoma, American Society of Clinical Oncology, Chicago, June 3, 2022 (oral)
77. Taylor ZL, Weisnicht AM, Poweleit E, Bernhardt MB, Miller TP, **Castellino SM**, Barreto J, Howard S, Ramsey LB. Utility of MTXPK.org for understanding your patient's methotrexate clearance. 2022 Betsy Poon Pharmacy Education Series, held in conjunction with the Children's Oncology Group (COG) Fall Meeting, September 20-24, 2022. New Orleans, LA (oral)
78. Taylor ZL, Weisnicht AM, Poweleit E, Bernhardt MB, Miller TP, **Castellino SM**, Barreto J, Howard S, Ramsey LB. The clinical decision support tool for high-dose methotrexate, MTXPK.org, is capable of accurately fitting individual patient data across diverse pediatric and adult populations with short and long infusions. The American College of Clinical Pharmacology (ACCP), September 25-27, 2022, Bethesda, MD
79. Jain T, Ji X, DeGroote N, Coxhead C, Mertens A, **Castellino SM**. Evaluating Age and Acuity and Severity of Illness at Initial Clinical Presentation in Patients with Leukemia and Lymphoma. Emory University Pediatric Hematology and Oncology Fall Research Retreat, November 2022, Braselton, GA. (Oral Presentation)
80. Cathcart A, **Castellino SM,** Sohn H, Mertens A, Ji X. The Relationship of Structural Racism and Acuity of Initial Illness in Patients with Solid Tumors. Emory University Pediatric Hematology and Oncology Fall Research Retreat, November 2022, Braselton, GA. (Oral Presentation)
81. *A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow.* Am Society of Hematology Dec. 11, 2022 New Orleans, LA (oral)
82. Parsons SK, Keller FG, Pei Q, Rodday AM, Belsky J, Wu Y, Punnett A, Henderson TO, Kelly KM, **Castellino SM**. Peripheral neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role od Protocol-Stipulated Dose Modification in Children's Oncology Group (COG) AHOD1331 Study. Am Society of Hematology Dec. 11, 2022 New Orleans, LA (poster)
83. Garofalo A, Alig SK, Schroers JS, Shyam R, Olsen M, Kurtz D, Rossi C, Schultz A, Kathuria KR, Liu CL, Spina V, Flerlage JE, **Castellino SM**, Advani RH, Rossi D, Lynch RC, Casasnovas O, Marks L, Link MP, Andre M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Viral cfDNA Profiling Reveals Distinct subtypes and Stratifies Risk In Hodgkin Lymphoma. Am Society of Hematology Dec. 11, 2022 New Orleans, LA (oral)
84. Alig SK, Esfahani MS, Li MY, Adams RM, Garofalo A, Jin MC, Olsen M, Telenius A, Sworder B, Schroers JS, King DA, Kurtz D, Rossi C, Schultz A, Kathuria KR, Liu CL, Spina V, Flerlage JE, **Castellino SM**, Advani RH, Rossi D, Lynch RC, Casasnovas O, Marks L, Link MP, Andre M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified by Comprehensive Noninvasive Profiling. Dec. 11, 2022 Am Society of Hematology Dec. 11, 2022 New Orleans, LA (oral)
85. Miller T, DeGroote NP, Taylor Z, Pommert L, Awoniyi O, Board S, Ugboh N, Joshi V, Weisinicht A, Ambrosino N, Bernhardt M, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey

LB. Severe Adverse Events Associated with Concentrations of High Dose methotrexate in Pediatric Acute lymphoblastic Leukemia Patients. Dec. 12, 2022 Am Society of Hematology Dec. 11, 2022 New Orleans, LA (oral)

86. Schwartz CL, Pei Q, Keller FG, Cho SY, Hodgson DC, McCarten KM, Wu Y, Kelly KM, **Castellino SM**. Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331. Am Society of Hematology Dec. 11, 2022 New Orleans, LA (poster)
87. Mumme HL, Bhasin SS, Nawaz M, Thomas BE, Huang C, DeRyckere D, **Castellino SM**, Wechsler DS, Raikar SS, Porter C, Graham DK, Bhasin M. A Single cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow. Dec. 12, 2022 Am Society of Hematology Dec. 11, 2022 New Orleans, LA (oral)
88. Ji X, Hu X,* Lewis R, Monroe C, Lipscomb J, **Castellino S**, Mertens A. "Association between Continuous Medicaid Coverage and Survival among Children with Cancer." 11th Annual Southeastern Pediatric Research Conference. Atlanta, Georgia. June 3, 2022. (poster)
89. Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, **Milgrom SA**, Parikh R, Hodgson D, Castellino S, Hoppe BS. A Survey of Children's Oncology Group Hodgkin Lymphoma Members Regarding the Role of Radiotherapy in the Management of Relapsed/Refractory Hodgkin Lymphoma. ASTRO 2022. Poster.
90. Flerlage J, Birz S, Castellino S, Appel B, Furner B, Graglia L, Henderson T, Hodgson D, Hoppe B, Kahn J, Keller F, Kessel S, Le C, Le M, Lucas J, McCarten K, Metzger M, **Milgrom S**, Parsons S, Pei Q, Wu Y, Zhou Y, Watkins M, Volchenbaum S, Kelly K. Advancing Pediatric Hodgkin Lymphoma Research Through NODAL. ISHL 2022. Poster.
91. Cathcart A**, Castellino SM,** Sohn H, DeGroote N, Mertens A, Ji X. Association Between Structural Racism and Acuity of Illness at Initial Presentation in Pediatric Patients with Solid Tumors. Georgia CTSA Southeast Regional Clinical and Translational Science Conference. March 2023, Pine Mountain, GA. (Poster Presentation)
92. Cathcart A, **Castellino SM,** Sohn H, DeGroote N, Mertens A, Ji X. Association Between Structural Racism and Acuity of Illness at Initial Presentation in Pediatric Patients with Solid Tumors. ACTS/Translational Science Meeting. April 2023, Washington, DC. (Poster Presentation)
93. Cathcart A, **Castellino SM,** Sohn H, Mertens A, Ji X. The Relationship of Structural Racism and Acuity of Initial Illness in Patients with Solid Tumors. Emory University Pediatric Hematology and Oncology Spring Research Retreat, May 2023, Atlanta, GA. (Oral Presentation)
94. Cathcart A, **Castellino SM,** Sohn H, DeGroote N, Mertens A, Ji X. Association Between Structural Racism and Acuity of Illness at Initial Presentation in Pediatric Patients with Solid Tumors. 9th Annual Health Services Research Day. May 2023, Atlanta, GA. (Poster Presentation)
95. Landier W, Bhatia S, Richman JS, Campos Gonzalez PD, Cherven B, Keith KE, Chollette V, Mitchell SA, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Gilkey MB, Colditz GA, Klosky JL. HPV vaccine initiation in a contemporary multi-site cohort of childhood cancer survivors: Oral Abstract at the International Symposium on Late Complications after Childhood Cancer. Atlanta, GA. June 15-17, 2023.
96. Ji X,* Hu X, Lipscomb J, Lewis R, Mertens A, **Castellino S**. "Continuous Medicaid Coverage is Associated with Improved Survival Among Children Newly Diagnosed with Cancer." 9th Annual Health Services Research Day. Atlanta, Georgia. May 3, 2023. (poster)
97. Miller TP, Strange L, DeGroote NP, Cossen K, Henderson M, Bernardo S, Chukoian L, Clegg E, Lahey A, Schlesinger J, Wang P, **Castellino SM**. Hemoglobin A1c and Association with Toxicities during Induction for Acute Lymphoblastic Leukemia. American Society of Pediatric Hematology/Oncology; 2023 May 12; Fort Worth, TX, USA. (poster)

98. Ji X,* Hu X, Mertens A, Leisenring W, Nathan P, Armstrong G, **Castellino S**, Kirchhoff A. "Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study." American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. June 2-6, 2023. (oral)
99. Ji X,* Zhang X, Bai S, Stock W, Yabroff KR, Mertens A, **Castellino SM**. "Health insurance continuity is associated with survival in children, adolescents, and young adults with blood cancer." American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. June 2-6, 2023.(oral)
100. Ji X,* Hu X, Mertens A, Leisenring W, Nathan P, Armstrong G, **Castellino SM**, Kirchhoff A. "Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: a report from the Childhood Cancer Survivor Study (CCSS)." CCSS Investigator Meeting. Atlanta GA, June 14-15, 2023.(oral)
101. Ji X,* Hu X, Mertens A, Leisenring W, Nathan P, Armstrong G, **Castellino S**, Kirchhoff A. "Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: a report from the Childhood Cancer Survivor Study (CCSS)." International Symposium on Late Complications After Childhood Cancer (ISLCCC). Atlanta GA, June 15-17, 2023. (oral)
102. Ji X,* Hu X, Lipscomb J, Lewis R, Mertens A, **Castellino S**. "Continuous Medicaid Coverage is Associated with Improved Survival Among Children Newly Diagnosed with Cancer." 9th Annual Health Services Research Day. Atlanta, Georgia. May 3, 2023. (oral)
103. Ji X,* Zhang X, Bai S, Stock W, Yabroff KR, Mertens A, **Castellino S**. "Lacking Health Insurance Continuity Is Associated with Worse Survival Among Children, Adolescents, and Young Adults Newly Diagnosed with Blood Cancer." Academy Health Annual Research Meeting. Seattle, WA. June 24-27, 2023. (oral)
104. Ji X,* Shi K, Ruddy K, Zhao J, Mertens A, Yabroff KR, **Castellino S**, Han X. "Association of Medicaid Expansion with Treatment Receipt, Delays in Treatment Initiation, and Survival Among Young Adult Women with Breast Cancer." Academy Health Annual Research Meeting. Seattle, WA. June 24-27, 2023.(oral)
105. Cathcart A, **Castellino SM,** Sohn H, DeGroote N, Mertens A, Ji X. Association Between Structural Racism and Acuity of Illness at Initial Presentation in Pediatric Patients with Solid Tumors. Pediatric Early Career Researcher Conference. August 2023, Atlanta, GA. (Poster Presentation)
106. Cherven B, Aye J, Bhatia S, Richman JS, Campos González PD, Keith KE, Chollette V, Mitchell SA, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Gilkey MB, Colditz GA, Landier W, Klosky JL. HPV vaccine initiation in a contemporary multi-site cohort of childhood cancer survivors. Oral Abstract at the Children's Oncology Group Annual Meeting, Adolescent and Young Adult Committee, September 7, 2023, Atlanta, Georgia.
107. Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM**. Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. ACTS/Translational Science Meeting. April 2023, Washington, DC. (Poster)
108. Herrera A*. LeBlanc M, **Castellino SM et.al**. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). American Society of Clinical Oncology June 2023, Chicago IL (oral, plenary)
109. Casey DL, McCarten K, Pei Q, Milgrom SA, Belsky JA, Cho SY, Keller FG, Punnett A, Hoppe BS, Kelly KM, **Castellino SM**. Stage IV Pediatric Hodgkin Lymphoma: A Report from the Children's Oncology Group AHOD1331 Trial. ISHL 2023. Oral presentation.
110. W Landier, S Bhatia, JS Richman, PD Campos Gonzalez, Y Chen, B Cherven, KE Keith, V Chollette, SA Mitchell, J Aye, **Castellino SM**, MM Gramatges, S Lindemulder, TB Russell,

LM Turcotte, MB Gilkey,GA Colditz, JL Klosky. HPV Vaccine Initiation in a Contemporary Multi-Site Cohort of Childhood Cancer Survivors: A Report from the HPV PROTECT Study. Oral webinar presentation at the HPV Cancer Center Consortium Webinar. Nov 2nd, 2023. ONLINE.

111. **Castellino SM**, Li H, Herrera AF, Punnett A, Leblanc M, Parsons SK, Hodgson D, Keller F, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Song JY, Sonali M, Friedberg JW, and Kelly KM. Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Oral Presentation)

112. Marks LJ, McCarten K, Pei Q, Wu Y, Kelly KM, Schwartz C, Wolden S, Friedman DL, **Castellino SM**, Appel B. Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)

113. Henderson TO, Hu B, Keller F, Pei Q, Wu Y, Hoppe B, Milgrom S, Yao S, Khan N, Giulino Roth L, Mailhot R, Cho S, Parsons SK, Kahn JM, Duvall AS, Hinds PS, LaCasce A, Grover NS, Allen PB, Evens AM, Schoder H, **Castellino SM**, Kelly KM. AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)

114. Roth LG, Keller F, Melgar Toledo M, **Castellino SM**, Forlenza CJ, Catalan M, Krystal J, Lamble A, Rao AV, Molina Morales F, Cooper S, Luisi F, Gonzalez Llano O, Lopez KA, Mauz-Koerholz C, Hoppe B, Shen J, Pillai P, Marinello P, Kelly KM. Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)

115. Rutherford SC, Li H, Herrera AF, Leblanc M, Ahmed S, Davison KL, Casulo C, Bartlett NL, Tuscano JM, Hess B, Torka P, Kumar P, Jacobs RW, Song JY, **Castellino SM**, Kahl BS, Leonard JP, Smith SM, Friedberg JW, Evens AM. Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged >60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Oral Presentation)

116. Alig SK, Esfahani MS, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin M, Olsen M, Telenius A, Mutter JA, Schroers-Martin J, Sworder BJ, Rai S, King D, Schultz A, Bölgeholz JL, Su S, Kathuria KR, Liu CL, Kang X, Langfitt DM, Pobre-Piza KF, Tian F, Strohband MJ, Spina V, Tousseyn T, Buedts L, Fornecker LM, **Castellino SM**, Advani RH, Rossi D, Lynch RC, Ghesquieres H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, Andre M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Oral Presentation)

117. Williams AM, Rodday AM, Pei Q, Henderson TO, Keller F, Punnett A, Kelly KM, **Castellino SM**, Parsons SK. Longitudinal Differences By Treatment Arm in Health-Related Quality of Life Among High Risk Pediatric Hodgkin Lymphoma Patients Treated on the Children's Oncology Group AHOD1331 Study. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Oral Presentation)

118. Zhang X, **Castellino SM**, Yabroff KR, Stock W, Bai S, Mertens AC, Lipscomb J, Ji X.

Health Insurance Continuity Is Associated with Stage at Diagnosis Among Children, Adolescents, and Young Adults Newly Diagnosed with Lymphoma. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)

119. Pabari R, McCarten K, Flerlage JE, Lai H, Mauz-Koerholz C, Dieckmann K, Palese M, , **Castellino SM**, Kelly KM, Stoevesandt D, Kurch L. CNS Involvement in Pediatric Hodgkin Lymphoma: A Comprehensive Retrospective Analysis from the Staging, Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL) Group. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)
120. Toner K, Dave H, Pezzella G, Pei Q, Horton TM, Kelly KM, Roth LG, **Castellino SM**, Bollard CM. Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)
121. Jain T, Ji X, Degroote N, Himes A, Coxhead C, Khanna A, Cathcart A, Miller TP, Blum KA, Tarquinio K, Mertens AC, **Castellino SM**. Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)
122. **Castellino SM**, Rebecca Williamson Lewis, Karen E Effinger, Ann C. Mertens, Joseph Lipscomb, and Xu Ji. Impact of Survivorship Care Plans (SCP) on Mortality in a Contemporary Cohort of Pediatric Patients Diagnosed with a Blood Cancer. American Society of Hematology (ASH) Conference, December 2023, San Diego, CA. (Poster Presentation)
123. Jain T, Ji X, Degroote N, Himes A, Coxhead C, Khanna A, Cathcart A, Miller TP, Blum KA, Tarquinio K, Mertens AC, **Castellino SM**. Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. American Society of Pediatric Hematology-Oncology (ASPHO) Conference, April 2024, Seattle, WA. (Poster Presentation)
124. Campos González PD, Klosky JL, Gilkey MB, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Landier W. A provider-focused communication intervention to increase HPV vaccine uptake in the pediatric oncology setting: Pre- and post-intervention survey of vaccine-related provider practices. Abstract presented at the National Cancer Institute's HPV Cancer Center Consortium 8th Annual Meeting, April 17, 2024, Lexington, Kentucky.
125. Klosky J, **Castellino SM.** "A stepped wedge trial of a healthcare provider–focused intervention to increase human papillomavirus (HPV) vaccine initiation among survivors of childhood cancer." American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. May 31-June 4, 2024.(oral)
126. Landier W, Campos González PD, Richman JS, Chen Y, Gilkey MB, Cherven B, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Keith KE, Salem AJ, Chollette V, Mitchell SA, Colditz GA, Bhatia S, Klosky JL. A stepped wedge trial of a healthcare provider-focused intervention to increase human papillomavirus (HPV) vaccine uptake among childhood cancer survivors. Abstract presented as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3, 2024, Chicago, Illinois.
127. Klosky JL, Campos González PD, Richman JS, Chen Y, Gilkey MB, Cherven B, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Keith KE, Salem AJ, Chollette V, Mitchell SA, Colditz GA, Bhatia S, Landier W. A stepped wedge trial of a healthcare provider-focused intervention to increase human papillomavirus (HPV) vaccine uptake among childhood cancer survivors. Abstract presented as an oral presentation at the International Symposium on Late Complications after Childhood Cancer, June 29, 2024,

Lucerne, Switzerland.

128. Cathcart A,* **Castellino SM**, Zhang L, Wasilewski-Masker K, Hong A, Sohn H, Ji X. "Association of Residential Economic and Racial Segregation with Metastatic Disease at Diagnosis in Pediatric Patients with Solid Tumors." (Poster) Presentation at the 17th Xu Ji, PhD, MSPH May 23, 25 Page 15 American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Los Angeles, CA. September 21-24, 2024.
129. Ji X,* Zhang L, Han X, Sohn H, Meggett K, Lewis RW, **Castellino SM**, "Association of Residential Economic and Racial Segregation with Pediatric Cancer Survival." (Poster) Presentation at the 17th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Los Angeles, CA. September 21-24, 2024.
130. Hu X,* **Castellino SM**, Srivastava DK, Nathan P, Armstrong G, Mertens A, Kirchhoff AC, Ji X. "Adherence to Guideline-Recommended Cardiac Screening in Medicaid-Enrolled Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS)." (Poster) Presentation at the 2024 ASCO Quality Care Symposium. San Francisco, California. September 27-28, 2024.
131. Milgrom SA, Hoppe BS, Renfro L, Wu Y, Schwartz CL, Constine LS, Hodgson D, McCarten DM, Kelly KM, **Castellino SM**, Keller FG. Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Children's Oncology Group AHOD 0431. American Society for Radiation Oncology, Washington, DC, September 29-October 2, 2024. (Oral presentation)
132. Miller TP*, DeGroote NP, Raney LF, Taylor ZL, O'Brien MM, Pommert L, Brown A, Board SG, Bernhardt B, Schafer ES, **Castellino SM**, Ramsey LB. "Comparison of clinical factors and toxicities associated with HDMTX administrations requiring glucarpidase in pediatric patients with leukemia, lymphoma, and osteosarcoma." International Society of Paediatric Oncology, Honolulu, HI, October 17-20, 2024. (Poster)
133. **Castellino SM**. Li H, Herrera AF, Punnett A, LeBlanc M, Parsons SK, Keller FG, Richard Drachtman R, Lamble A, Forlenza C, Doan A, Rutherford S, Evens A, Hodgson D, Little R, Smith M, Dillon H, Song J, Smith S, Friedberg JW, Kelly KM. Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL). 13th International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 26-28, 2024 (oral)
134. Milgrom SA, Hoppe BS, Renfro L, Wu Y, Schwartz CL, Constine LS, Hodgson D, McCarten DM, Kelly KM, **Castellino SM,** Keller FG. Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Sub-Study of Children's Oncology Group AHOD 0431. 13th International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 26-28, 2024. (poster) Selected for ISHL poster award.
135. Williams AM, Rodday AM, Renfro, LA, Henderson TO, Keller FG, Kelly KM, **Castellino SM**, Parsons SK. Longitudinal Differences By Treatment Arm in Health-Related Quality of Life Among High Risk Pediatric Hodgkin's Lymphoma Patients Treated on the Children's Oncology Group AHOD 1331 Study. Group-Based Trajectories of Health-related Quality of Life (HRQoL) among Patients with High-Risk Pediatric Hodgkin Lymphoma treated on the Children's Oncology Group (COG) AHOD 1331 Study. 13th International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 26-28, 2024. (poster)
136. Ji X,* Lewis RW, Jain T, Zhang L, **Castellino SM**. "Racialized Economic Segregation is Associated With Acuity and Severity of Pediatric Leukemia at Presentation." (Poster) Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting. San Diego, California. December 7-10, 2024.
137. Jain T,* Ji X, Degroote N, Himes A, Coxhead C, Williamson-Lewis R, Khanna A,

Cathcart A, Miller TP, Blum KA, Tarquinio K, **Castellino SM**. Acuity of Illness at Initial Presentation Mediates Early Mortality in Adolescent and Young Adult Leukemia. American Society of Hematology (ASH) Conference, December 7-10, 2024, San Diego, CA. (Poster Presentation)

138. Stevenson J*, Khanna A, Hawk A, Morse A, Alao O, Jordan K, Ji X, Sohn H, **Castellino SM**, Miller TP. "Association of race and social deprivation on the incidence and severity of adverse events in induction in children with acute lymphoblastic leukemia." American Society of Hematology Annual Meeting, San Diego, CA, December 7-10, 2024. (Poster)
139. Muñiz* J, Lee K, Ji X, Arellano M, **Castellino SM**. "Patient and Neighborhood Characteristics Associated with Frontline Therapeutic Clinical Trial Enrollment Among Adolescents and Young Adults (AYAs) with Hematologic Malignancies at Affiliated Pediatric and Adult Centers." Association for Clinical and Translational Science National Conference, April 15-17, 2025, Washington, DC. Poster presentation.
140. Muñiz J, Ji X, Lee K, **Castellino SM**. "The Association between High Acuity of Illness and Frontline Therapeutic Clinical Trial Enrollment Among Children and Adolescents and Young Adults (AYAs) with Lymphoma." American Society of Pediatric Hematology/Oncology National Conference, May 7-10, 2025, Louisville, KY. Poster presentation.
141. *Milgrom SA, Paganetti H, Dama H, Renfro L, Wu Y, Meyer I, Parsons SK, Punnett A, Charpentier A, Lo AC, Mailhot Vega R, Keller FG, Kelly KM, Hoppe BS, **Castellino SM**, Hodgson D. Subsequent Neoplasm Risk after Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Analysis of a Multi-Institutional Children's Oncology Group Trial. The American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, May 30-June 3, 2025, Chicago, IL. (Oral presentation)
142. Lewis RW,* Ji X, Mertens A, **Castellino SM**. "Why did the Childhood Cancer Survivor Die? Comparison of Death Certificate vs. Medical Record Review Cause of Death in a Contemporary Cohort of Childhood Cancer Survivors." (Poster) presentation at the 2025 International Symposium on Late Complications After Childhood Cancer (ISLCCC). Seattle, Washington. June 19-21, 2025. presentation at the 2025 International Symposium on Late Complications After Childhood Cancer (ISLCCC). Seattle, Washington. June 19-21, 2025.
143. Hu X,* Klosky J, Srivastava DK, Zhang Z, Brinkman T, Krull K, Nathan P, Snyder C, Armstrong G, Nolan V, Yasui Y, **Castellino SM**, Ji X. "Association Between State Opioid Limiting Laws and Opioid Prescription Among Medicaid-enrolled Survivors of Childhood Cancer." (Poster)
144. Khanna A., **Castellino SM**, Cummings J, Rana SA, Klosky JL, & Ji X. (2025, October). "Healthcare provider perspectives on the end of the COVID-19 Medicaid continuous enrollment provision: Implications for childhood cancer survivors (Abstract 513426)." ASCO Quality Care Symposium, Chicago, IL. October 2025, Chicago, IL. (Poster)
145. Mailhot Vega RB, Fisher CL, Crisp AM, Mullis MD, Cacchio R, Gardner A, Causer J, Michel E, Weinbrenner D, Hayes R, Lynch E, Hernandez T, Parker AS, Guo Y, **Castellino SM**, Mobley EM. "Race, ethnicity, and insurance inequities in Hodgkin lymphoma (HL) treatment and survivorship care in the US: A study in progress." 6th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma. Berlin, Germany. October 15 – 18, 2025.

b. **Regional:**

1. *Stribling JT, Petty JK, Hurt GJ, Garvin AJ, **Castellino SM**. Small Cell Carcinoma of the Ovary in a Child with Compelling Family History. - NC Residents Symposium, Myrtle Beach, NC. August 2006 (poster)
2. *Summers RJ, Felker J, Mitchell S, Park S, Carter A, Goldsmith KC, Macdonald T, Pauly M, Cash T, Aguilera D, Porter C, **Castellino SM**, Wechsler DS, Graham DK. Mapping a Path to

Precision in Childhood Cancer: The Aflac Cancer and Blood Disorders Center Precision Medicine Program. 2018 Southeastern Pediatric Research Conference: Precision Medicine, June 8, 2018, Atlanta GA (poster)

3. *Edington H, Chandrakasan S, Miller T, DeGroote N, Mertens A, **Castellino SM** "Immunoglobulin administration and hypogammaglobulinemia during pediatric acute leukemia therapy" accepted for poster presentation at the Association for Clinical and Translational Science (ACTS) Translational Science 2020 Conference (April 14-17, 2020; *virtual presentation -COVID19 pandemic*)
4. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM**. Evaluating the Association of Age with Acuity and Severity of Illness at Initial Clinical Presentation in Patients with Leukemia and Lymphoma. Georgia CTSA Southeast Regional Clinical and Translational Science Conference. March 2023, Pine Mountain, GA. (Poster)
5. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM.** Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. 12th Annual Southeastern Pediatric Research Conference. June 2023, Atlanta, GA. (Poster)

c. **Institutional:**

1. *Tuell D, **Castellino SM**. Congenital Sideroblastic Anemia. East Tennessee University 18th Annual Student/ Resident Research Day, Johnson City TN 2002. (poster)
2. *Keenum C, Sabnis H, Williamson R, Patterson B, Effinger K, Bergsagel J, Silverman E, Mertens A, **Castellino SM**. Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy. Emory SOM, Annual Student/Resident Research Day, April 2016, Atlanta GA (poster)
3. *Silverman EA, Effinger KE, Allen K, **Castellino SM**. Screening and Detection of Endocrine Late Effects in Pediatric Hodgkin Lymphoma Survivors Following Contemporary Therapy. Emory Undergraduate Research Symposium, May 2019, Atlanta GA (poster)
4. *Joshi V, DeGroote N, Miller T, **Castellino SM**. Association of hemoglobin A1c with incident hyperglycemia during induction therapy for pediatric leukemia. Emory Undergraduate Research Symposium, May 2021, Atlanta GA (oral)
5. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM.** Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. 9th Annual Health Services Research Day. May 2023, Atlanta, GA. (Poster)
6. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM**. Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. Emory University Pediatric Fellow Research Day Competition. May 2023, Atlanta, GA. (Poster)
7. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM**. Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia. Emory University Pediatric Hematology and Oncology Spring Research Retreat, May 2023, Atlanta, GA. (Oral)
8. *Jain, T, Ji X, Himes A, DeGroote N, Coxhead C, Mertens A, **Castellino SM.** Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia. Pediatric Early Career Researcher Conference. August 2023, Atlanta, GA. (Poster)
9. *Jain T, Ji X, Degroote N, Himes A, Coxhead C, Khanna A, Cathcart A, Miller TP, Blum KA, Tarquinio K, Mertens AC, **Castellino SM.** Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia and Lymphoma. Emory University Pediatric Hematology-Oncology Fall Research Retreat, October 2023, Buford, GA. (Poster Presentation)

4. **Research Focus:**
Areas of investigation: Clinical trials in Hodgkin Lymphoma (HL), identification of biomarkers of cardiovascular injury (CV) after cancer, and study of outcomes during and following (survivorship) childhood cancer therapy. Identification of biomarkers will facilitate precision medicine and design of intervention trials to attenuate late effects and enhance outcomes.

5. **Grant Support:**
   a. **Active Support:**
      1. **Federally Funded:**
         i. R37 CA288560 (Mailhot-Vega; Mobley) 02/2025 – 01/2030 0.6 CM
         National Cancer Institute $2,290,338
         Determining Barriers Leading to Inferior Survival for Black and Hispanic Patients with Hodgkin Lymphoma: A Patient-Centered Study
         The study evaluates mechanisms to explain differences in outcomes for subgroups of survivors of Hodgkin lymphoma, The analysis utilizes quantitative data from the national longitudinal electronic health record PCORnet network innovatively linked to stem cell transplant data through the Center for International Blood and Marrow Transplant Research (CIBMTR) and qualitative data from patients' and caregivers' decision-making experiences and (iii) maximize data utility
         Role: CoI

         ii. LLS (Mailhot-Vega; Mobley) 07/2024 – 06/2027
         Leukemia and Lymphoma Society $741,832
         Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast
         Major Goals: Underinsured and uninsured patients diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. This is particularly relevant in the Southeast, where Alabama, Florida, and Georgia have not participated in Medicaid expansion. Using the OneFlorida+ database, we will examine differences by insurance status in the receipt and quality of HL treatment
         Role: Co-I

         iii. R50 CA285492-01 (Castellino) 8/1/2024- 7/3/2029 4.8 CM
         Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma.
         Role:PI
         iii. X01 (MPI: Castellino, Brown) 7/1/2024-6/30/2024
         Gabriella Miller Kids First Initiative: Germline sequencing of Hodgkin Lymphoma
         To determine the frequency of P/LP variants in CPG and IEI genes among individuals with cHL.
         Role: MPI

         iv. CA210872P2 (Castellino) 7/1/2022-6/30/2026 0.6 CM
         Department of Defense $388,750
         An Integrative Radiogenomic Framework for Predicting Treatment failure in Children, Adolescents and Young Adults with Hodgkin Lymphoma. We will use circulating tumor DNA and define and trace response for patients with high-risk Hodgkin lymphoma treated on AHOD1331
         Role: PI
         v. R01 0000055923 (Wolfson) 4/01/2021 – 3/30/2026 0.60 CM
         NIH/Emory Sub with University of Alabama, Birmingham $26,292/yr.
         Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and

Young Adults with Acute Lymphoblastic Leukemia
Goals: To compare patterns of adherence and predictors of oral chemotherapy between childhood and adolescent and young adult patients with leukemia.
Role: Consortium institution PI

vi. Gage-Bouchard (PI) 1/1/2022-12/31/2026 0.6 CM
R01CA258667-01A1 $564,367
Behavioral parenting Skills as Novel Target for Improving Pediatric medication Adherence
Goals: Examine aspects of parenting at the episode and daily levels and to develop an intervention to enhance medication adherence in young children in children 2-10
Role: Co-I

vii. U10CA180886 (Hawkins, PI) 3/1/2022 – 3/29/2032 1.8 CM
Scientific Chair – Hodgkin Lymphoma Committee- Children's Oncology Group
Role: Disease Chair

viii. Hayashi (PI) 7/1/2022-6/30/2025 0.24 CM
Department of Defense
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors.
Role (CoI)

2. **Private Foundation Funded:**

i. Graham (PI) 7/1/2017-6/30/2023 1.2 calendar month (CM)
CURE $4,500,000
Aflac Precision Medicine: An investigation to create a systematic institutional approach to seek novel molecular abnormalities and potential therapy targets for all high-risk cancer patients from diagnosis onward.
Role (Co-I; Precision Medicine Protocol Vice-Chair)

ii. Ji (PI) 7/1/2022-6/30/2023 0.12 CM
Rally Foundation 22YIN50 $50,000
Assessing neighborhood deprivation and racial segregation for childhood cancer
Role (CoI)

iii. Wadhwa (PI) 1/1/2021-12/31/22 0.12 CM
St. Baldrick's Foundation $4000
Body Composition and Adverse Outcomes in pediatric Hodgkin Lymphoma
Role: Co-I

iv. Ji/Castellino (MPI) 7/1/20222-6/30/2024 1.8CM
Leukemia and Lymphoma Society $499,219
Impact of health insurance on mortality for children and AYAs newly diagnosed with blood cancer: A population-based multistate evaluation. The study will utilize SEER-Medicaid data to examine the impact of insurance continuity on survival.

v. Mailhoit-Vega/Mobley 07/2024 – 06/2027
Leukemia and Lymphoma Society $741,832
Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast
Role Co-I

3. **Contracts:**

i. none

4. **Other:**

i. none

b. **Pending Support:**

none

c. **Previous Support:**

i. American Society of Pediatrics Department Chairman's Award 1996- 1998
Title: Retroviral Gene Marking of Umbilical Cord Blood Derived Hematopoietic Stem cells
Role: Trainee

ii. Castellino (PI)
Bare Necessities Pediatric Cancer Foundation 2000-2001
Title: Cellular Trafficking of p21-ras

iii. Children's Oncology Group (COG) Castellino (PI) 07/01/06-06/30/09
Survivorship/Cancer Control Consortium
Title: Cancer Survivorship and Cancer Control Consortium
The goal of this study was to participate in a cadre of COG studies of survivorship and cancer control initiatives.
Role: Institutional PI- Wake Forest

iv. Castellino (PI) 01/01/06-06/30/2010
Lance Armstrong Young Investigator Award $130,000
A pilot study of donepezil in pediatric brain tumor survivors after cranial irradiation
The goal of this study was to evaluate the feasibility and toxicity of administering a 6-month open label trial of the acetylcholinesterase inhibitor donepezil to pediatric brain tumor survivors at risk for cognitive dysfunction.
Role: PI

v. WFU Cancer Center Intramural Grant Castellino/Hundley (PI) 09/01/07-08/31/09
Variance of magnetic resonance imaging (MRI) markers of cardiovascular risk in young adult survivors following childhood cancer therapy.
The goal of this study was to evaluate the feasibility of recruiting a young adult cancer survivor population at risk for cardiovascular toxicity and to establish the variance of cardiac MRI measures in this population and a healthy young adult cohort, in order to plan for a larger evaluation of cMRI as a biomarker.
Role: Co-PI

vi. R25 CA122061-01A1 Avis (PI) 07/01/08 – 06/30/13 NIH/NCI
Postdoctoral Training in Cancer Control Research
This postdoctoral training program in cancer control with an emphasis on cancer survivorship is designed for MDs or PhDs and focuses on didactic coursework, mentored research and seminars. All trainees have protected time to do research and receive formal training in cancer survivorship, cancer control, public health and behavioral sciences, NIH grant preparation and participate in interdisciplinary seminars and interests' groups.
Role: Trainee (salary support for dedicated research effort through June 2012)

vii. Intramural Grant Castellino (PI) 09/01/2008-08/31/2011
Comprehensive Cancer Center of WFU and Institute for Regenerative Medicine $20,000
Evaluation of variance in circulating endothelial progenitor cell numbers in long term survivors of childhood cancer.
The goal of this study was to evaluate the feasibility of detecting circulating endothelial progenitor cells in a young adult population of healthy volunteers compared to a population of childhood survivors who received anthracycline chemotherapy and thoracic radiation as curative therapy.

Role: PI

viii. WFU Intramural Gallagher (PI) 06/01/10 – 05/31/12
Translational Science Institute $50,000
Effect of angiotensin-(1-7) on childhood sarcomas
This team science project will evaluate the variance of the anti-angiogenic peptide angiotensin-(1-7) and other components of the rennin angiotensin system in childhood sarcoma patients prior to and following completion of therapy. We are concurrently beginning pre-clinical testing of angiotensin-(1-7) in animal xenografts of childhood sarcoma.
Role: Co- Investigator

ix. R25 J Blatt (PI) 2/2011-2/2013
AYA cancer Survivorship Curriculum and Consultation Hotline for Providers, Survivor, and Families.
Role: Co-I

x. Castellino (PI) 07/01/11 – 06/30/12
St. Baldrick's Childhood Cancer Foundation $70,142
Evaluating Aortic Stiffness in Pediatric Brain Tumor Survivors
This study will provide preliminary data evaluating a novel mechanistic link between radiation injury to the cerebrovascular system and subclinical cardiac dysfunction. It applies cardiac MRI concurrent with transcranial doppler measurement of cerebrovascular function in children who received cranial or cranio-spinal radiation therapy.

xi. Castellino (PI) 8/1/2012-7/31/2015 (NCE) NIH/NCI
1R21CA159557-01A1 $624,000
Resonance Imaging Trial for Heart bioMarkers (RITHM) in AYA Cancer Survivors
This study is an observational clinical trial with a cross-sectional and longitudinal design to evaluate the cardiac MRI in detecting subclinical markers of cardiac injury after anthracycline therapy.

xii. Bhatia (PI) 12/1/2013-2015 $5000+ PCI
A trial of low dose Tamoxifen in young adult survivors who received therapeutic radiation to the thorax.
Role: Institutional PI

xiii. Children's Oncology Group (COG) 7/1/2013-2015 $2000/patient+ Workload Intensity
A cooperative grant for clinical trials for children and adolescents with cancer
Role: Institutional PI

xiv. Castellino (PI) 9/1/2013-8/01/2015
St. Baldrick Childhood Cancer Foundation $98,742
This study is a cross-sectional pilot to evaluate cardiovascular and cerebrovascular function in brain tumor survivors.

xv. Gallagher (PI) 10/1/2013-8/31/2016
Leukemia and Lymphoma Society $200,000
Prevention of Doxorubicin-Induced Cardiotoxic Late Effects by Ang-(1-7)
This study is a laboratory-based evaluation of a young animal model to examine cardio-protective strategies after and during exposure to anthracycline.
Role: Co-I

xvi. Castellino (PI) 9/1/2013-7/31/2015
WFU Vaccine Center Pilot Award $20,000
Evaluation of uptake of HPV vaccine in AYA cancer survivors via linkage of NC Immunization registry to the Cancer center database of survivors.
Role PI

xvii .Castellino (PI) 1/1/2015-12/31/2016
Hyundai Foundation $250,000
Evaluating Inflammation and Mediators of Cardiovascular Aging in Childhood Cancer Survivors.
This study evaluates blood-based biomarkers accompanying the phenotypic data from the RITHM study.
Role: PI (Aug 2015- 12/31/2016- acting PI due to institution move)

xvii.Parsons (PI) 6/1/2014-5/31/2017
Leukemia and Lymphoma Society $400,000/year
Proof of Paradigm in Cost-Effectiveness Analysis with Novel Therapeutics
This study is a cost effectiveness evaluation infrastructure project linked to the COG AHOD1331 trial.
Role: CoI

xviii.Danhauer (PI) 1/1/2016-12/31/2017 (NCE 7/1/2018)
R21 CA 181563-01 $1,178,800
Work Ability in Adolescent and Young adult Cancer Survivors. The major aims of this project are to (1) delineate common themes in the experiences of young adult (YA) survivors in how physical, cognitive, and psychosocial issues following cancer diagnosis and treatment have affected their work ability, educational attainment, labor force participation, and occupation; and (2) identify common patterns in how work or school adjustments in response to the effects of cancer diagnosis and treatment influence YA survivors' occupational and educational outcomes.
Role: Co-I

xix.Sabnis (coPI); Castellino (coPI) 7/1/2016-10/1/2019 (NCE) 0.36 calendar year
Bristol-Myers Squibb (CA180-640) $150,000
LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in children and adolescents. An infrastructure grant awarded to establish a cohort of pediatric patients who received tyrosine kinase inhibitor therapy for a hematologic malignancy. The goal is to establish a long-term prospective study to understand the late toxicities of these novel agents in the growing child Role – (Mentor/CoPI)

xx. COG-U10CA98543 12/1/2014-2020 0.96 calendar year
PI: Adamson $105,000
Study Chair for COG: AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in children and Adolescents.
Role: Study Chair

xxi. Ji/Castellino, MPI 3/01/2021-2/28/2023 0.60 CM
R03CA259665-01 $157,405 total for 2 years
Understanding the impact of the Affordable Care Act on cancer treatment and outcomes for adolescents and young adults (AYA)
This study examines survival, stage at presentation and disparities in AYA cancers in the national Cancer Database (NCDB) relative to Medicaid expansion in the US.
Role (MPI)

xxii. U01CA246567 (Landier/Klosky, MPI) 09/18/2020 – 08/31/2023 .30 CM
Emory Sub-award with University of Alabama, Birmingham $455,766 total for 3 years
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors Receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial
Test the effectiveness and evaluate the implementation of a provider -directed intervention to increase HPV vaccine uptake in young cancer survivors seen in pediatric oncology practices.
Role: Co-Investigator

xxiii. U48DP006377-02-00 (Kegler, PI) 09/30/2020 – 09/29/2022 .96 CM
Centers for Disease Control $685,181 total for 2 years
Mertens: SIP 20-004. Effect of Survivorship Care Plans on Cancer Mortality
This study will evaluate our single institution experience with survivorship and post treatment morbidity and mortality to the childhood cancer survivor having a survivorship care plan.
Role: Co-Investigator

xxiv. U10CA180886 (Adamson, PI) 3/28/2019 – 3/29/2023 .57 CM
NIH/Emory Sub with Children's Hospital of Philadelphia $47,308
S1826: A Phase III Randomized Study of Nivolumab (Opvido) Plus AVD or Brentuximab vedotin (Adcetris) plus AVD in patients (age>/=12 years) with newly diagnosed Advanced Stage Classical Hodgkin Lymphoma
This study is a phase III clinical trial comparing novel agents in an AVD chemotherapy backbone for advanced stage Hodgkin Lymphoma.
Role: Study Chair Pediatric/COG enrollments

xxv. Miller, T (PI) 09/21/2017-08/31/2022 (0.6 CM in kind)
NIH/NCI (K07CA211956-01A1)
The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children's hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.
Role: Mentor team

xxvi. Ji (PI) 12/20/2021-11/20/2023 0.6 CM (yr. 2)
NIH/NCI R03CA267456-01 $169,872
Understanding the impact of the Affordable care act on healthcare coverage and utilization and outcomes for childhood cancer survivors in the Childhood Cancer Survivor Study. This analysis will focus specifically on those with public insurance coverage and examine the association of insurance coverage to health care utilization overall and concordance with guideline directed care.
Role: CoI

II. Bibliography:

a. Published and Accepted Research Articles (clinical, basic science, other) in Refereed Journals:

1. Baraniuk JN, Lundgren JD, Goff J, Mullol J, **Castellino SM**, Merida J. Shelhamer JH, Kaliner MA. Calcitonin gene-related peptide in human nasal mucosa. *Am J Physiol* 1990; 258: L81-8.
2. Baraniuk JN, **Castellino SM**, Lundgren JD, Goff J, Mullol J, Merida J, Shelhamer JH, Kaliner MA. Neuropeptide Y in human nasal mucosa. *Am J Respir Cell Mol Biol* 1990; 3:165-73.
3. **Castellino SM**, Elion GB, Griffith OW, Dewhirst MW, Kurtzberg J. Cattley RC, Scott P, Bigner DD, Friedman HS. Development of a model of melphalan induced gastrointestinal toxicity in mice. *Cancer Chemother Pharmacol* 1993; 31:376-80.
4. **Castellino SM**, Friedman HS, Elion GB, Ong ET, Marcelli SL, Page R, Bigner DD, Dewhirst MW. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. *Br J Cancer* 1995; 7:1181-7.
5. Parsons SK, **Castellino SM**, Lehmann LE, Eickhoff CE, Tarbell NJ, Sallan SE, Weinstein HJ, Billet AL. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. *Bone Marrow Transplant* 1996; 17:763-8.

6. **Castellino SM**, Traweek T, Rosoff PM. Ewing's tumor and papillary adenocarcinoma of the thyroid in a 14-year-old girl. *J Pediatr Hematol Oncol* 1998; 20:177-80.
7. **Castellino SM**, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in pediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics, and significance. *Br J Haematol* 1999; 104:189-194.
8. **Castellino SM**, Kurtzberg J, Smith C. Retroviral vector-mediated gene transfer into umbilical cord blood-derived megakaryocyte and platelet progenitors. *Biol Blood Marrow Transplant 1999*; 5:215-221.
9. **Castellino SM**, Powers R, Kalwinsky D, DeVoe M. Abdominal rhabdoid tumor presenting as fetal hydrops: a case report. *J Pediatr Hematol Oncol* 2001; 23: 258-9.
10. **Castellino S,** Lensing S, Riely C, Rai S, Davila R, Fleckenstein J, Levstik M, Taylor S, Dean P, Kippenbrock S, Pope J, Carr J, Strickland DK, Hudson M. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St. Jude Children's Research Hospital Hepatitis C seropositive cohort. *Blood* 2004; 103:2460- 2466.
11. **Castellino SM**, Casillas J, Hudson M, Mertens A, Whitton J, Brooks S, Zeltzer L, Ablin A, Castleberry R, Hobbie W, Kaste S, Robison L, Oeffinger K. Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization and health related behaviors from the childhood cancer survivor study (CCSS). *J Clin Oncol* 2005; 23:6499-507.
12. **Castellino SM,** Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG. Outcomes in childhood AML in the absence of transplantation in first remission - Children's Cancer Group (CCG) studies 2891 and CCG 213. *Pediatr Blood Cancer* 2008; 50(1):9-16
13. Metzger M, **Castellino SM**, Hudson MM, Rai SN, Kaste SC, Krasin MJ, Kun LE, Pui C, Howard SC. Effect of Race on the Outcome of Pediatric Patients with Hodgkin Lymphoma. *J Clin Oncol* 2008; 26(8):1282-8.
14. Hill G, **Castellino S**, Williams D. Cardiac myxoma following treatment for childhood neuroblastoma. *Pediatr Cardiology* 2009; 30(3):340-2.
15. Martinez-Borges AR, Petty JK, Hurt G, Stribling JT, PressJZ, **Castellino SM**.Familial Small Cell Carcinoma of the Ovary. *Pediatr Blood and Cancer* 2009; 53(7):1334-6
16. Keller FG, **Castellino SM**, Nachman JB. What is the best treatment for Children with limited stage Hodgkin Lymphoma? *Current Hematol Malig Rep*. 2009; 4(3):129-35
17. **Castellino SM**, Muir A, Shah A, Shope S, McMullen K, Ruble K, Barber A, Davidoff A, Hudson MM. Hepato-Biliary Late Effects in Survivors of Childhood and Adolescent Cancer - A Report from the Children's Oncology Group. *Pediatr Blood Cancer* 2010, 54(5):663-9. NIHMS144364
18. Lansdale M, **Castellino S**, Marina N, Goodman P, Hudson MM, Mertens AC, Smith SM, Leisenring W, Robison LL, Oeffinger KC. Knowledge of Hepatitis C Virus Screening in Long-Term Pediatric Cancer Survivors: A Report from the Childhood Cancer Survivor Study. *Cancer* 2010; 116(4): 974-82
19. Casillas J, **Castellino SM**, Hudson MM, Mertens AC, Lima IS, Liu Q, Zeltzer LK, Yasui Y, Robison LL, Oeffinger KC. Impact of Insurance Type on Survivor-Focused and General Preventive Health Care Utilization in Adult Survivors of Childhood Cancer: The Childhood Cancer Survivor Study (CCSS). *Cancer* 2011; 117(9):1966-75. PMID: 21509774 PMCID: 3433164
20. **Castellino SM**, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and Mortality in Long-Term Survivors of Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study. *Blood*. 2011 Feb 10;117 (6):1806-16. Epub 2010 Oct 29. PMID: 21037086
21. Geiger AM **Castellino SM**. Delineating the Age Ranges Used to Define Adolescents and Young Adults. *J Clin Oncol*. 2011 Jun 1;29(16): e492-3. PMID: 21482981
22. Mulder RL, van Dalen EC, Van den Hof M, Bresters D, Koot BG, **Castellino SM**, Loke Y, Leclercq E, Post PN, Caron HN, Postma A, Kremer LC. Hepatic late adverse effects after

antineoplastic treatment for childhood cancer. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD008205. Review.
23. **Castellino SM**, Tooze JA, Flowers L, Hill DF, McMullen KP, Shaw EG, Parsons SK. Toxicity and Efficacy of the Acetylcholinesterase (AChe) Inhibitor Donepezil in Childhood Brain Tumor Survivors: A Pilot Study. *Pediatr Blood Cancer*. 2012 Sep;59(3):540-7 PMID 22238217
24. **Castellino SM**, Tooze JA, Flowers L, Parsons SK. The peabody picture vocabulary test as a pre-screening tool for global cognitive functioning in childhood brain tumor survivors. J Neurooncol. 2011 Sep;104(2):559-63. doi: 10.1007/s11060-010-0521-1. Epub 2011 Jan 12. PMID: 21225316; PMCID: PMC3681605.
25. Geiger AM, **Castellino SM**, Tooze JA, Altschuler A, Month S, Mertens AC, Nekhlyudov L, Greene SM. Potential role of Community-Based Healthcare System Data in Research on Survivors of Adolescent and Young Adult Cancer. *J Adolesc Young Adult Oncol* 2013 Jun; 2(2):53-58 PMID 2378140
26. Blatt J, McLean TW, **Castellino SM**, Burkhart CN. A review of contemporary options for medical management of hemangiomas, other vascular tumors and vascular malformations. *Pharmacol Ther*. 2013 139(3):327-33 PMID 23665062
27. Wang X, Liu W, Sun CL, Armenian SH, Hakonarson H, Hageman L, Ding Y, Landier W, Blanco JG, Chen L, Quinones A, Ferguson D, Winick N, Ginsberg JP, Keller F, Neglia JP, Desai S, Sklar CA, **Castellino SM**, Cherrick I, Dreyer Z, Hudson MM, Robison LL, Yasui Y, Relling MV, Bhatia S. Hyaluronan Synthase 3 (HAS3) Variant and Anthracycline-Related cardiomyopathy – A report from the Children's Oncology Group. *J Clin Oncol* 2014; 32(7):647-53. PMID: 24470002
28. Effinger KE, Migliorati CA, Hudson MM, McMullen KP, Kaste SC, Ruble K, Guilcher GM, Shah AJ, **Castellino SM**. Oral and Dental late Effects in Survivors of Childhood Cancer: A Children's Oncology Group Report. *Support Care Cancer* 2014; 22(7):2009-19 PMID 24781353; PMCI: PMC4118932
29. Witkowski L**,** Carrot-Zhang J**,** Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian R, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, **Castellino SM**, Lamovec J**,** Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulias V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WJ, Clarke BA, Yasser Riazalhosseini YA, Hasselblatt M, Majewski J**,** Foulkes WD**.** Germline and somatic *SMARCA4* mutations characterize small cell carcinoma of the ovary, hypercalcemic type. *Nature Genet*. 2014 46(5):438-43. PMID:24658002.
30. Grimes K, Kratzer T, Russo K, Bourland D, **Castellino S.** Occult GI Bleeding in a 15 yo Pediatric Cancer Survivor. *J Pediatr Gastroenterol Nutr*. 2014 Dec 23. PMID25061718
31. **Castellino SM**, Ullrich NJ, Whelen MJ, Lange BJ. Developing Interventions for Cancer – Related Cognitive Dysfunction in Childhood Cancer Survivors. *J Natl Cancer Inst*. 2014 106(8). PMID:25080574; PMC4155432
32. Wilson CL, Stratton K, Leisenring WL, Oeffinger KC, Nathan PC, Wasilewski-Masker K, Hudson MM, **Castellino SM**, Stovall M, Armstrong GT, Brinkman TM, Krull KR, Robison LL, Ness KK. Decline in physical activity level in the Childhood Cancer Survivor Study cohort. *Cancer Epidemiol Biomarkers Prev*. 2014 Aug; 23(8):1619-27. PMID:2484262
33. Hudson MM, Oeffinger KC, Jones K, Brinkman T, Krull K, Mulrooney DA, Mertens A, **Castellino SM**, Casillas J, Gurney J, Nathan PC, Leisenring W, Robison LL, Ness KK. Age-Dependent Changes in Health Status in the Childhood Cancer Survivor Cohort. *J Clin Oncol*. 2015 Feb; 3395):479-91
34. Shaw PH, Reed DR, Yeager N, Zebrack B, **Castellino SM**, Bleyer A. Adolescent and Young Adult (AYA) Oncology in the United States: A Specialty in its Late Adolescence. *J Pediatr Hematol Oncol*. 2015 Apr;37(3):161-9. PMID: 25757020
35. Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Rotter JI, Taylor KD, Chen YI, Armenian SH, Winick N, Ginsberg JP, Neglia JP, Oeffinger

KC, **Castellino SM**, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. *J Clin Oncol.* 2016 Mar 10; 34(8):863-70. PMID: 26811534

36. Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GM, Huang JT, Pelletier W, Perkins JL, Rivard LS, Schechter T, Shah AJ, Wilson KD, Wong K, Grewal S, Armenian S, Meacham LR, Mulrooney DA, **Castellino SM.** Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. *Biol Blood Marrow Transplant.* 2016 May 22(5):782- 95 PMID:26802323
37. Lown EA, Hijiya N, Zhang N, Srivastava DK, Leisenring WM, Nathan PC, **Castellino SM**, Devine KA, Dilley K, Krull KR, Oeffinger KC, Hudson MM, Armstrong GT, Robison LL, Ness KK. Patterns and predictors of clustered risky health behaviors among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *Cancer*. 2016 Sep 1;122(17):2747-56. PMID:27258389
38. Metrock LK, Summers RJ, Park S, Gillespie S, **Castellino S**, Lew G, Keller F. Utility of peripheral blood immunophenotyping by flow cytometry in the diagnosis of pediatric acute leukemia. *Pediatr Blood Cancer* 2017 Mar. PMID:28333411
39. Summers RJ, Metrock LK, Park S, Gillespie S, **Castellino S**, Lew G, Keller FG. Comment on: Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018 Feb; 65(2).
40. Keller FK, **Castellino SM,** Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton A, Bush R, Constine LS, Schwartz CL. Results of the AHOD0431 Trial of Response Adapted Therapy and a Salvage Strategy for Limited-Stage Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group. *Cancer.* 2018 Aug1; 124(15):3210-3219. PMID:29738613
41. Parsons SK, Kelly MJ, Cohen JT, **Castellino SM**, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.*Br J Haematol*. 2018 Jul;182(2):212-221. PMID:29707774
42. Jordan JH, **Castellino SM**, Meléndez GC, Klepin HD, Ellis LR, Lamar Z, Vasu S, Kitzman DW, Ntim WO, Brubaker PH, Reichek N, D'Agostino Jr RB, Hundley WG. Left Ventricular Mass Change after Anthracycline Chemotherapy. Circ Heart Fail. 2018 Jul;11(7): e004560. PMID: 29991488
43. Blum KA, Keller FG, **Castellino S**, Phan A, Flowers CR. Incidence and outcomes of lymphoid malignancies in adolescent and young adult (AYA) patients in the United States. *Br J Haematol*. 2018 Nov; 183(3):385-399 PMID: 30095154
44. Miller L, Kobayashi S, Pauly M, Lew G, Saxe D, Keller F, Qayed M, **Castellino S**. Evaluating approaches to enhance survival in children with hypodiploid acute lymphoblastic leukaemia (ALL). *Br J Haematol*. 2019 May; 185(3):613-616. PMID: 30255927
45. Sabnis HS, Keenum C, Lewis RW, Patterson B, Bergsagel J, Effinger KE, Silverman E, Mertens AC, **Castellino SM**. Growth Disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. *Br J Haematol.* 2019 May;185(4):795-799. PMID: 30407613
46. Miller LH, Keller FK, Mertens AC, Klein M, Allen K, ***Castellino SM**, *WoodsWG. Impact of fluid overload and infection on respiratory adverse events development during induction therapy for childhood acute myeloid leukemia. *Pediatric Blood Cancer*, 2019 Dec;66(12): e27975 **(* co-senior author)** PMID: 31502412
47. Mulder RL, Bresters D, Van den hof M, Koot BG, **Castellino SM**, Loke YKK, Post PN, Postma

A, Szőnyi LP, Levitt GA, Bardi E, Skinner R, van Dalen EC. Hepatic late adverse effects after antineoplastic treatment for childhood cancer *Cochrane Database Syst Rev*. 2019 Apr 15.;4:CD008205 PMID: 30985922

48. **Castellino SM**, Allen KE, Pleasant K, Keyes G, Poehling KA, Tooze JA. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. *J Cancer Surviv*. 2019 Oct;13(5):730-738. PMID:31342304
49. Cherven B, **Castellino SM**, Chen Y, Wong FL, York JM, Wasilewski-Masker K, Hudson MM, Bhatia S, Klosky JL, Landier W. Intent and subsequent initiation of human papilloma vaccine among young cancer survivors. *Cancer*. 2019 Nov 1;125(21):3810- 3817 PMID: 31291010
50. Kahn J, Kelly KM, Pei, Q, Bush R, Friedman DL, Keller FG, Bhatia S, Henderson TO, Schwartz CL, **Castellino, SM**. Survival by race and ethnicity in children and adolescents with Hodgkin Lymphoma: A Children's Oncology Group Study. *J Clinical Oncology*, 2019 Nov 10;37(32):3009-3017. PMID: 31539308
51. McFatrich M, Brondon J, Lucas NR, Hinds PS, Maurer SH, Mack JW, Freyer DR, Jacobs SS, Baker JN, Mowbray C, Wang M, **Castellino SM**, Leahy AB, Reeve BB. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research. *Cancer*. 2020 Jan 1;126(1):140-147. PMID: 31553494
52. Reeve BB, McFatrich M, Mack JW, Maurer SH, Jacobs SS, Freyer DR, Withycombe JS, Baker JN, **Castellino SM**, Lin L, Lucas NR, Hinds PS. Validity and reliability of the Pediatric Patient-Reported Outcomes – Common Terminology Criteria for Adverse Events. *J Natl Cancer Inst.* 2020 Nov 1;112(11):1143-115. 2PMID: 31999349
53. Singh P, Wang X, Hageman L, Chen Y, Magdy T, Landier W, Ginsberg JP, Neglia JP, Sklar CA, **Castellino SM**, Dreyer Z, Hudson MM, Robison LL, Blanco JG, Relling MV, Burridge P, Bhatia, S. Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer – A COG ALTE03N1 report. *Cancer* 2020 Sep 1;126(17):4051-4058 PMID 32413235
54. Edington HJ, Sutton KS, Bennett C, Chandrakasan S, Sterner-Allison J, **Castellino SM**. Dealing with a Critical National Shortage – Approaches to Triaging Immune Globulin Supply in Pediatric Hematology and Oncology. *Pediatr Blood Cancer*, 2020 Jul 67 (7) Epub 2020 Apr 24. PMID **32329568**
55. Bailur JK, McCachren SS, Pendleton KE, Vasquez JC, Lim HS, Duffy A, Doxie D, Kaushal A, Foster CJR, DeRyckere D, **Castellino SM,** Kemp M, Qiu P, Dhodapkar MV, Dhodapkar KM. Risk associated alterations in marrow T cells in pediatric leukemia. *JCI Insight.* 2020 Aug 20;5(16):e140179. PMID: 32692727
56. Sabnis HS, Minson KA, Monroe C, Allen K, Metts JL, Cooper TM, Woods WG, **Castellino SM**, Keller FG. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. *Leuk Res. 2020* Sep; 96:106421. epub 2020 Jul 12. PMID: 32683126
57. *West ZE, ***Castellino SM**, Monroe C, Thomas AS, McCracken C, Miller TP. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia. *Leuk Lymphoma* 2020 Dec1:1-14 PMID 33258395(*co-first authors)
58. Oeffinger KC, Stratton KL, Hudson MM, Leisenring WM, Henderson TO, Howell RM, Wolden SL, Constine LS, Diller LR, Sklar CA, Nathan PC, **Castellino SM**, Barnea D, Smith SA, Hutchinson RJ, Armstrong GT, Robison LL. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. *J Clin Oncol.* 2021 Feb 25: JCO2001186. doi: 10.1200/JCO.20.01186. Online ahead of print. PMID: 33630659
59. Liu R, Li D, Sun F, Rampoldi A, Maxwell JT, Wu R, Fischbach P, **Castellino SM**, Du Y, Fu H, Mandawat A, Xu C. Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. *Stem Cell Res Ther*. 2020 Nov 5;11(1):470. PMID: 33153480

60. Shinn K, Wetzel M, DeGroote NP, Keller F, Briones M, Felker J, **Castellino S**, Miller TP.Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia. *Pediatr Blood Cancer.* 2020 Nov;67(11):e28570. PMID: 32881268
61. Labudde EJ, DeGroote NP, Smith S, Ebelhar J, Allen KE, **Castellino SM**, Wasilewski-Masker K, Brock KE. Evaluating palliative opportunities in pediatric patients with leukemia and lymphoma. *Cancer Med. 2021* Apr;10(8):2714-2722. PMID: 33754498.
62. Ehrhardt MJ, Flerlage JE, Armenian SH, **Castellino SM**, Hodgson DC, Hudson MM. Integration of Pediatric Hodgkin Lymphoma Treatment and late Effects Guidelines: Seeing the Forest beyond the Trees. *J Natl Compr Canc Netw.* 2021 Jun 30;19(6):755-764, PMID 34214967
63. Smith SM, Sabnis HS, Williamson Lewis R, Effinger KE, Bergsagel J, Patterson B, Mertens A, Sakamoto KM, Schapira L, **Castellino SM**. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias. *BMC Cancer 2021*, Apr 29;21(1):474. doi: 10.1186/s12885-021-08182-z.*BMC Cancer*. 2021. PMID: 33926411
64. Sabnis HS, Shulman DS, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, Fabrizio VA, Whitlow C, Winchester M, Agresta L, Turpin B, Wechsler DS, DuBois SG, Glade-Bender J, **Castellino SM**, Shukla N. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. *J Clin Oncol* 2021 Dec 1; 39 (34): 3822-3828 PMID 34591650
65. Maurer S, Reeve B, Mack J, McFatrich M, Li L, Withycombe J, Jacobs S, Baker J, **Castellino SM**, Freyer D. Patients, caregivers, and Clinicians differ in Performance Status Ratings: Implications for Pediatric Cancer Clinical Trials. *Cancer*. 2021 Oct 1;127(19):3664-3670.PMID: 34196962
66. Ji X, **Castellino SM**, Mertens AC, Zhao J, Nogueira L, Jemal A, Yabroff K, Han X. Association of Medicaid Expansion with Cancer Stage and Disparities in Newly Diagnosed Young Adults. *J Natl Cancer Inst.* 2021 May 21:djab105. doi: 10.1093/jnci/djab105. Online ahead of print.*J Natl Cancer Inst*. 2021. PMID: 34021352
67. Mailhot Vega RB, **Castellino SM**, Pei Q, Parsons S, Roberts KB, Hodgson D, Charpentier AM, Fitzgerald TJ, Kessel SK, Keller FG, Kelly K, Hoppe BS. Evaluating Disparities in Proton Radiotherapy Use in a Contemporary Children's Oncology Group Trial for Advanced Stage Hodgkin Lymphoma. *Int J Part Ther*. 2021 Oct 28;8(3):55-57..PMID: 35127976
68. Kahn JM, Zhang X, Kahn AR, **Castellino SM**, Neugut AI, Schymura MJ, Boscoe FP, Keegan THM. Racial disparities in Children, Adolescents, and Young Adults with Hodgkin Lymphoma Enrolled in the New York State Medicaid program. *J Adolesc Young Adult Oncol* 2021 Oct 8. PMID: 34637625
69. Bardi E, Mulder RL, vanDalen EC, Bhatt NS, Ruble KA, Bugis J, **Castellino SM**, Constine LS, den Hoed CM, Green DM, Koot BG, Levitt G, Szonyi L, Wallace WH, Skinner, R, Hudson MM, Kremer LCM, Effinger KE, Bresters D. Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group. *Cancer Treatment Rev* 2021 2021 Nov;100:102296. doi: 10.1016/j.ctrv.2021.102296. epub 2021 Sep 20.
70. Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, **Castellino SM**, Franklin A, Keller FG, Shukla N. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin Lymphoma. *Blood Adv*. 2021 Dec 28; 5 (24):5519-5524
71. Kahn JM, Pei Q, Friedman DL, Kaplan J, Keller FG, Hodgson D, Wu Y, Appel BE, Bhatia S, Henderson TO, Schwartz CL, Kelly KM, **Castellino SM**. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials. *Lancet Haem* 9:1 e49-e57, January 2022
72. Ji X, Hu X, **Castellino S**, Mertens A, Yabroff KR, Han X. Narrowing Insurance Disparities Among Children and Adolescents with Cancer Following the Affordable Care Act. *JNCI Cancer Spectrum*. 2022 Jan 5;6 91 PMID 35699500

73. Summers R, **Castellino SM**, Porter CC, MacDonald TJ, Basu GD, Szelinger S, Bhasin MK, Cash T, Caster AB, Castellino RC, Fangusaro JR, Mitchell S, Pauly MG, Pencheva B, Wechsler DS, Graham DK, Goldsmith KC. Comprehensive genomic profiling of high-risk pediatric cancer patients has a measurable impact on clinical care. *JCO Precision Oncology* 2022 Apr: 6 e2100451 PMID: 35544730
74. Gilbert JR, Sabnis HS, Radzievski R, Doxie DB, DeRyckere D, **Castellino SM**, Dhodapkar K.J Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia *J. Immunother Cancer*. 2022 Jun;10(6):e004774 PMID: 35710294
75. Stevenson J, DeGroote NP, Keller F, Brock KE, Bergsagel DJ, Miller TP, Cornwell P, Fasano R, Chonat S, **Castellino SM**. Characteristics and outcomes of Pediatric Oncology patients at risk for guardians declining transfusion of blood components. *Cancer Rep*, Jul 6:e1665. PMID 35792092
76. Withycombe JS, McFatrich M, Hinds PS, Bennett A, Lin L, Maurer SH, Lucas NR, Mann CM, **Castellino SM**, Baker JN, Reeve BB. Can Steps per Day Reflect Symptoms in Children and Adolescents Undergoing Cancer Treatment? *Cancer Nurs*. 2022 Sep-Oct 01;45(5) PMID: 35131975
77. Miller TP, Getz KD, Li Y, Demissei BG, Adamson PC, Alonzo TA, Burrows E, Cao L, **Castellino SM**, Daves MH, Fisher BT, Gerbing R, Grundmeier RW, Krause EM, Lee J, Lupo PJ, Rabin KR, Ramos M, Scheurer ME, Wilkes JJ, Winestone LE, Hawkins DS, Gramatges MM, Aplenc R. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. *Lancet Haematol*. 2022 Jul 20; S2352-3026
78. Parekh A, Keller FG, McCarten KM, Kessel S, Cho S, Pei Q, Wu Y, **Castellino SM**, Constine LS, Schwartz CL, Hodgson D, Kelly KM, Hoppe BS. Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis. *Blood* 2022 Jun 28 PMID 35763667
79. Withycombe JS, Eldridge R, Jin Y, Gu H, **Castellino SM**, Sears DD. Metabolites Associated With Fatigue and Physical Activity in Childhood Cancer. *Biol Res Nurs*. 2022 Jul;24(3):350-361. doi: 10.1177/10998004221085029. Epub 2022 Apr 25.PMID: 35466716
80. Labudde EJ, DeGroote NP, Ebelhar J, Massie AM, Allen KE, **Castellino SM**, Wasilewski-Masker K, Brock KE. Evaluating Palliative Opportunities Across the Age Spectrum in Children and Adolescent Patients with Cancer. *J Adolescent and Young Adult Oncology.* Aug 2022 11 (4):402-409
81. Patel, PA, DeGroote, NP, Jackson, K, Cash, T, **Castellino SM**, Jaggi, P, Esbenshade, AJ, Miller, TP. Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia. *Cancer* 2022 Dec. 128(23):4129-4138
82. **Castellino SM**, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett, Dave H, Henderson TO, Hoppe BS, Charpentier AN, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy In Pediatric High-Risk Hodgkin Lymphoma*. New Engl. J. Med 2022 Nov.; 387:1649-1660. PMID 36322844*
83. Jacobs S, Whitycombe J, **Castellino SM,** Lin L, Mack JW, McFatrich Molly, Baker JN, Freyer DF, Maurer SH, Mowbray C, Hinds PS, Reeve BB. Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events. *Ped Blood and Cancer* 2022 Dec 69(12): e29986. PMID 36151978
84. Landier W, Bhatia S, Richman JS, Campos Gonzalez PD, Cherven B, Chollette V, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Colditz GA, Gilkey MB, Klosky JL. Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT

intervention. *BMC Pediatr.* 2022 Sep 12;22(1):541. doi: 10.1186/s12887-022-03562-1. PMID: 36096775
85. Ji X, Shi K, Mertens AC, Zhao J, Yabroff KR, **Castellino SM**, Han X. Survival in young adults with cancer is associated with Medicaid expansion through the Affordable Care Act. *Journal of Clinical Oncology*. 2023;41(10):1909-1920. PMID: 36525612
86. Miller TP, Li Y, Masino AJ, Vallee E, Burrows E, Ramos M, Alonzo TA, Gerbing R, **Castellino SM**, Hawkins DS, Lash TL, Aplenc R, Grundmeier RW. Automated Ascertainment of Typhlitis From the Electronic Health Record. *JCO Clin Cancer Inform*. 2022 Sep;6:e2200081. doi: 10.1200/CCI.22.00081. PMID: 36198128.
87. Ebelhar J, DeGroote NP, Massie AM, Labudde E, Allen KE, **Castellino SM**, Wasilewski-Masker K, Brock KE. Differences in palliative opportunities across diagnosis groups in children with cancer. *Pediatric Blood Cancer* 2023 Jan;70(1):e30081. doi: 10.1002/pbc.30081. Epub 2022 Nov 15.PMID: 36377714
88. Bhasin SS, Thomas BE, Summers RJ, Sarkar D, Mumme H, Pilcher W, Emam M, Raikar SS, Park SI, **Castellino SM**, Graham DK, Bhasin MK, DeRyckere D. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis. Sci Rep. 2023 Aug 2;13(1):12556. doi: 10.1038/s41598-023-39152-z. PMID: 37532715; PMCID: PMC10397284.
89. Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, **Castellino SM**. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1025-1030. doi: 10.1016/j.ijrobp.2023.02.020. Epub 2023 Mar 2. PMID: 36868525; PMCID: PMC10363760.
90. Stevenson J, DeGroote NP, Keller F, Brock KE, Bergsagel DJ, Miller TP, Cornwell P, Fasano R, Chonat S, **Castellino SM**. Characteristics and outcomes of pediatric oncology patients at risk for guardians declining transfusion of blood components. Cancer Rep (Hoboken). 2023 Jan;6(1):e1665. doi: 10.1002/cnr2.1665. Epub 2022 Jul 6. PMID: 35792092; PMCID: PMC9875642.
91. **Castellino SM**, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6:e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PMID: 37505794.
92. Pillsbury CE, Dougan J, Rabe JL, Fonseca JA, Zhou C, Evans AN, Abukharma H, Ichoku O, Gonzalez-Flamenco G, Park SI, Aljudi A, DeRyckere D, **Castellino SM**, Rafiq S, Langermann S, Liu LN, Henry CJ, Porter CC. Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun. 2023 Jul 17;3(7):1248-1259. doi: 10.1158/2767-9764.CRC-23-0056. PMID: 37465593; PMCID: PMC10351425.
93. Mailhot Vega RB, Harker-Murray PD, Forlenza CJ, Cole P, Kelly KM, Milgrom SA, Parikh RR, Hodgson DC, **Castellino SM**, Kahn J, Roberts KB, Constine LS, Hoppe BS. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):400-403. doi: 10.1016/j.ijrobp.2023.04.022. Epub 2023 Apr 26. PMID: 37116589.
94. Ji X, Shi KS, Ruddy KJ, Zhao J, Mertens AC, Yabroff KR, **Castellino SM**, Han X. Medicaid expansion is associated with treatment receipt, timeliness, and outcomes among young adults with breast cancer. JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad067. doi: 10.1093/jncics/pkad067. PMID: 37707583; PMCID: PMC10534051.
95. Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM, **Castellino SM**. Performance of the FACT-GOG-Ntx to Assess Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Pediatric High Risk Hodgkin Lymphoma: Report from the Children's Oncology Group AHOD 1331 Study. Journal of Patient-Reported Outcomes 2023 Nov 10:7(1):113 doi: 10.1186/s41687-023-00653-0.PMID: 37947987

96. Taylor ZL, Miller TP, Poweleit EA, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Chavana A, Bernhardt MB, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey LB. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023 Nov;16(11):2130-2143. doi: 10.1111/cts.13600. Epub 2023 Aug 3. PMID: 37503924; PMCID: PMC10651646.
97. Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P, Sarkar D, Ulukaya GB, Sabnis HS, Park SI, DeRyckere D, Raikar SS, Pauly M, Summers RJ, **Castellino SM**, Wechsler DS, Porter CC, Graham DK, Bhasin M. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia Nat Commun. 2023 Oct 5;14(1):6209. doi: 10.1038/s41467-023-41994-0.PMID: 37798266
98. Mumme HL, Raikar SS, Bhasin SS, Thomas BE, Lawrence T, Weinzierl EP, Pang Y, DeRyckere D, Gawad C, Wechsler DS, Porter CC, **Castellino SM,** Graham DK, Bhasin M, Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia**.** Genome Med. 2023 Oct 16;15(1):83. doi: 10.1186/s13073-023-01241-z.PMID: 37845689
99. Flerlage JE, Palese M, Mauz-Koerholz C, **Castellino SM.** Proceedings and Abstracts From the Fifth International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL) Meeting**.** J Pediatr Hematol Oncol. 2023 Dec 18:e1-e43. doi: 10.1097/. Online ahead of print.PMID: 38113171
100. Ji X, Hu X, Lipscomb J, Chow EJ, Mertens AC, **Castellino SM.** Utilization of cardiac tests in anthracycline-treated cancer survivors differs between young adults and children**.** Cancer Med. 2023 Dec;12(24):22056-22061. doi: 10.1002/cam4.6801. Epub 2023 Dec 9.PMID: 38070180
101. Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, **Castellino SM**, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature. 2024 Jan;625(7996):778-787. doi: 10.1038/s41586-023-06903-x. Epub 2023 Dec 11. PMID: 38081297; PMCID: PMC11293530.
102. Lo AC, Liu A, Liu Q, Yasui Y, **Castellino SM**, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open. 2024 Jan 2;7(1):e2351062. doi: 10.1001/jamanetworkopen.2023.51062. PMID: 38241048; PMCID: PMC10799264.
103. George PE, DeGroote NP, Henderson M, Jordan K, Ziworitin-Ogola C, **Castellino SM**, Miller TP. Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALL. Pediatr Blood Cancer. 2024 Mar;71(3):e30825. doi: 10.1002/pbc.30825. Epub 2023 Dec 25. PMID: 38146039; PMCID: PMC10843810.
104. Tie X, Shin M, Pirasteh A, Ibrahim N, Huemann Z, **Castellino SM**, Kelly KM, Garrett J, Hu J, Cho SY, Bradshaw TJ. Personalized Impression Generation for PET Reports Using Large Language Models. J Imaging Inform Med. 2024 Apr;37(2):471-488. doi: 10.1007/s10278-024-00985-3. PMID: 38308070; PMCID: PMC11031527.
105. Wyatt KD, Birz S, **Castellino SM**, Henderson TO, Lucas JT Jr, Pei Q, Zhou Y, Volchenboum SL, Furner B, Watkins M, Kelly KM, Flerlage JE. Accelerating pediatric hodgkin lymphoma research: the hodgkin lymphoma data collaboration (NODAL). J Natl Cancer Inst. 2024 May 8;116(5):642-646. doi: 10.1093/jnci/djae013. PMID: 38273668.
106. Hall MD, Howell RM, Jackson A, Owens CA, Hernandez S, **Castellino SM**, Ronckers CM, Constine LS, Bradley JA. Liver Late Effects in Childhood Cancer Survivors Treated With

Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):575-587. doi: 10.1016/j.ijrobp.2023.06.002. Epub 2023 Jul 20. PMID: 37480885
107. Golloshi K, Mitchell W, Kumar D, Malik S, Parikh S, Aljudi AA, **Castellino SM**, Chandrakasan S. HLH and Recurrent EBV Lymphoma as the presenting manifestation of MAGT1 Deficiency: A Systematic Review of the Expanding Disease Spectrum. J Clin Immunol. 2024 Jun 19;44(7):153. doi: 10.1007/s10875-024-01749-y. PMID: 38896122.
108. Zhang Z, Zhang D, Guo W, Fenton K, Narayanan S, Jain S, Jiang J, **Castellino SM**, Kelly KM, Cole PD, Keller FG, Garg A, Chia YL. Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma. Clin Cancer Res. 2024 Aug 1;30(15):3273-3281. doi: 10.1158/1078-0432.CCR-23-3655. PMID: 38810021; PMCID: PMC11292200.
109. Flerlage JE, Waters-Banker C, Fanale M, Beckerman R, **Castellino SM**, Liu N. A systematic literature review of clinical evidence and treatment burden in newly diagnosed high-risk pediatric patients with classical Hodgkin lymphoma. Pediatr Blood Cancer. 2024 Aug;71(8):e31027. doi: 10.1002/pbc.31027. Epub 2024 May 18. PMID: 38761013.
110. Pabari R, McCarten K, Flerlage J, Lai H, Mauz-Körholz C, Dieckmann K, Palese M, Kaste S, **Castellino SM**, Kelly KM, Stoevesandt D, Kurch L. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346. PMID: 39058968; PMCID: PMC11416590.
111. Chavana AN, Taylor ZL, DeGroote N, Lindsay HB, Sauer HE, Mason EJ, Schafer ES, Miller TP, **Castellino SM**, Pommert L, O'Brien MM, Ramsey LB, Bernhardt MB, Brown AL. Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct;71(10):e31213. doi: 10.1002/pbc.31213. Epub 2024 Jul 22. PMID: 39039774.
112. Williams AM, Rodday AM, Pei Q, Henderson TO, Keller FG, Punnett A, Kelly KM, **Castellino SM**, Parsons SK. Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. J Clin Oncol. 2024 Oct;42(28):3330-3338. doi: 10.1200/JCO.24.00038. Epub 2024 Jul 26. PMID: 39058966; PMCID: PMC11481752.
113. Herrera AF, LeBlanc M, **Castellino SM**, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17;391(15):1379-1389. doi: 10.1056/NEJMoa2405888. PMID: 39413375.
114. Shi KS, Ji X, Jiang C, Ruddy KJ, **Castellino SM**, Yabroff KR, Han X. Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2024 Oct 23;22(9):593-599. doi: 10.6004/jnccn.2024.7041. PMID: 39447607.
115. Heneghan MB, **Castellino SM**, Thompson LA. What Is Childhood Lymphoma? JAMA Pediatr. 2024 Nov 1;178(11):1234. doi: 10.1001/jamapediatrics.2024.3614. PMID: 39348101.
116. Zhang XE, **Castellino SM**, Yabroff KR, Stock W, Cornwell P, Bai S, Mertens AC, Lipscomb J, Ji X. Medicaid coverage continuity is associated with lymphoma stage among children and adolescents/young adults. Blood Adv. 2025 Jan 28;9(2):280-290. doi: 10.1182/bloodadvances.2024013532. PMID: 39531060; PMCID: PMC11786654.
117. Ji X, Zhang XE, Yabroff KR, Stock W, Cornwell P, Bai S, Mertens AC, Lipscomb J, **Castellino SM**. Health insurance continuity and mortality in children, adolescents, and young adults with

blood cancer. J Natl Cancer Inst. 2025 Feb 1;117(2):344-354. doi: 10.1093/jnci/djae226. PMID: 39276159; PMCID: PMC11807435.
118. Hoppe BS, Milgrom SA, Renfro LA, Wu Y, Schwartz CL, Constine LS, McCarten KM, Kelly KM, Hodgson D, **Castellino SM**, Keller FG. Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Mar 1;11(3):340-342. doi: 10.1001/jamaoncol.2024.5648. PMID: 39745710; PMCID: PMC11837869.
119. Lucotti S, Ogitani Y, Kenific CM, Geri J, Kim YH, Gu J, Balaji U, Bojmar L, Shaashua L, Song Y, Cioffi M, Lauritzen P, Joseph OM, Asao T, Grandgenett PM, Hollingsworth MA, Peralta C, Pagano AE, Molina H, Lengel HB, Dunne EG, Jing X, Schmitter M, Borriello L, Miller T, Zhang H, Romin Y, Manova K, Paul D, Remmel HL, O'Reilly EM, Jarnagin WR, Kelsen D, **Castellino SM**, Giulino-Roth L, Jones DR, Condeelis JS, Pascual V, Bussel JB, Boudreau N, Matei I, Entenberg D, Bromberg JF, Simeone DM, Lyden D. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell. 2025 Mar 20;188(6):1642-1661.e24. doi: 10.1016/j.cell.2025.01.025. Epub 2025 Feb 11. PMID: 39938515.
120. Greenzang KA, Montgomery KE, DuVall A, Roth ME, Krailo M, Nuño MM, Renfro L, DelRocco N, Doski J, Kelly K, **Castellino SM**, McNeer J, O'Brien MM, Reed D, Janeway K, Hinds PS, Zupanec S, Parsons SK. Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. J Natl Cancer Inst. 2025 Mar 31:djaf083. doi: 10.1093/jnci/djaf083. Epub ahead of print. PMID: 40163691.
121. Hu X, **Castellino SM**, Kirchhoff AC, Williamson Lewis RS, DeGroote NP, Cornwell P, Mertens AC, Lipscomb J, Ji X. Association Between Medicaid Coverage Continuity and Survival in Patients With Newly Diagnosed Pediatric and Adolescent Cancers. JCO Oncol Pract. 2025 Mar;21(3):380-390. doi: 10.1200/OP.24.00268. Epub 2024 Sep 30. PMID: 39348628.
122. Wadhwa A, Dai C, Kessel S, Richman JS, Shen W, Kahn JM, **Castellino SM**, Kelly KM, Friedman DL, Bhatia S. Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2025 Apr 3;34(4):560-567. doi: 10.1158/1055-9965.EPI-24-1231. PMID: 39817816; PMCID: PMC11968239.
123. Heneghan MB, Parsons SK, Keller FG, Renfro LA, Pei Q, Rodday AM, Wu Y, Punnett A, Belsky JA, Henderson TO, Kelly KM, **Castellino SM**. Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma. JCO Oncol Pract. 2025 Apr;21(4):526-534. doi: 10.1200/OP.24.00089. Epub 2024 Sep 20. PMID: 39303168; PMCID: PMC11922787.
124. Marks LJ, Wu Y, McCarten KM, Renfro LA, Pei Q, Kelly KM, Schwartz CL, **Castellino SM**, Appel BE. PET Response and Outcome in Low-Risk Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1. Pediatr Blood Cancer. 2025 May;72(5):e31606. doi: 10.1002/pbc.31606. Epub 2025 Feb 14. PMID: 39953678; PMCID: PMC11934935.
125. Klosky JL, Cherven B, Gilkey MB, Aye J, **Castellino SM**, Gramatges MM, Lindemulder S, Russell TB, Turcotte LM, Campos González PD, Skipper KE, Chollette V, Mitchell SA, Colditz GA, Bhatia S, Landier W. A framework-based guide for adapting and implementing primary care-based pediatric interventions to the pediatric oncology setting: HPV PROTECT as an exemplar. Cancer. 2025 May 1;131(9):e35857. doi: 10.1002/cncr.35857. PMID: 40297935; PMCID: PMC12038771.
126. Mumme HL, Huang C, Ohlstrom D, Bakhtiari M, Raikar SS, DeRyckere D, Qayed M, **Castellino SM**, Wechsler DS, Porter CC, Graham DK, Bhasin SS, Bhasin M. Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas. Nat Commun. 2025 May 2;16(1):4114. doi: 10.1038/s41467-025-59362-5. PMID: 40316535; PMCID: PMC12048633.
127. Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, **Castellino SM**, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial

PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiol Artif Intell. 2025 May;7(3):e240229. doi: 10.1148/ryai.240229. PMID: 39969278; PMCID: PMC12127956.

128. Monroe C, Muñiz JP, Leong T, Lewis RW, **Castellino SM**. Disparities in Clinical Trial Participation in Children and Adolescent Patients With a Hematologic Malignancy. Pediatr Blood Cancer. 2025 Jun;72(6):e31641. doi: 10.1002/pbc.31641. Epub 2025 Mar 7. PMID: 40055873.
129. Taylor ZL, Miller TP, Board SG, Poweleit EA, Chavana A, Weisnicht A, Brown AL, Bernhardt MB, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey LB. What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025 Jul;72(7):e31744. doi: 10.1002/pbc.31744. Epub 2025 Apr 20. PMID: 40254820.
130. Belsky, JA, Renfro LA, Keller FG, Hodgson DC, Punnett A, McCarten K, Cho SY, Wu Y, Kelly KM, **Castellino SM**, Schwartz CL. Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331, Pediatr Blood Cancer 2025 Sep;72(9):e31856.PMID: 40515508; PMCID: PMC12230980
131. Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, Parsons SK, Unger JM, Perry AM, Casulo C, Bartlett NL, Tuscano JM, Hess BT, Torka P, Kumar P, Jacobs R, Song JY, **Castellino SM**, Kahl B, Leonard JP, Smith SM, Friedberg JW, Evens AM. Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. J Clin Oncol. 2025 Sep 20;43(27):2968-2973. doi: 10.1200/JCO-25-00204. Epub 2025 Jun 16. PMID: 40523203; PMCID: PMC12353409.
132. Hoppe BS, Mailhot-Vega RB, Renfro LA, Pei Q, Charpentier AM, Parikh RR, Roberts KB, Keller FG, Punnett A, Parsons S, Voss SD, Alzaraki A, McCarten KM, Flampouri S, Kessel S, Wu Y, Cho SY, Kelly KM, **Castellino SM**, Hodgson DC. Comparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331. Int J Radiat Oncol Biol Phys. 2025 Jun 28:S0360-3016(25)04518-3. doi: 10.1016/j.ijrobp.2025.06.3876. Epub ahead of print. PMID: 40588069; PMCID: PMC12308618.
133. Zheng DJ, Rodday AM, **Castellino SM**, Renfro LA, Lerner D, Henderson TO, Wu Y, Kelly KM, Conti RM, Parsons SK. Caregiver At-Work Productivity Loss at the Time of a Child's Diagnosis With High-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD1331 Study. Pediatr Blood Cancer. 2025 Sep;72(9):e31841. doi: 10.1002/pbc.31841. Epub 2025 Jun 30. PMID: 40589014; PMCID: PMC12395594.
134. Williams AM, Rodday AM, Renfro LA, Wu Y, Henderson TO, Keller FG, Punnett A, Hodgson D, Kelly KM, **Castellino SM**, Parsons SK. Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma. J Natl Cancer Inst. 2025 Jul 23:djaf197. doi: 10.1093/jnci/djaf197. Epub ahead of print. PMID: 40700618.
135. Hu X, **Castellino SM**, Srivastava DK, Nathan PC, Armstrong GT, Snyder C, Kirchhoff AC, Ji X. Cardiomyopathy Screening Adherence Among Medicaid-Enrolled Long-Term Survivors of Childhood Cancer. Cancer Med. 2025 Aug;14(15):e71116. doi: 10.1002/cam4.71116. PMID: 40878971; PMCID: PMC12322921.
136. Ji X, Lewis R, Wasklouski K, Effinger K, Ward K, Jordan M, Klosky J, Lipscomb J, **Castellino SM**. “Survivorship care and mortality in a contemporary and diverse cohort of childhood cancer survivors.” JNCI September 2025- online

b. Preprints:

c. Manuscripts Submitted:

i. Milgrom SM, Paganetti H, Dama H; Renfro L, Wu Y, Meyer I, Parsons SK, Punnett A, MD, Charpentier AM, Lo A, Mailhot Vega, R, Keller FG, Kelly KM; Hoppe BS; **Castellino SM**, HodgsonD. Submitted JAMA Onc
ii. Ji X, Hu X, Nathan P, Leisenring W, Armstrong G, Mertens A, **Castellino SM**, Kirchhoff AC. "Medicaid enrollment changes among adult survivors of childhood cancer following Medicaid expansion: a report from the Childhood Cancer Survivor Study." Under review at JCO Oncology Practice.
iii. Hu X, **Castellino SM**, Srivastava DK, Nathan P, Armstrong G, Kirchhoff AC, Ji X. "Cardiac Screening Adherence in Medicaid-enrolled Long-term Survivors of Childhood Cancer." Under review at Cancer Medicine.

d. Symposium Contributions:

1. Kahn JM, Mauz-Korholz C, Hernandez T, Milgrom SA, **Castellino SM**. Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432420. doi: 10.1200/EDBK_432420. PMID: 38788179.
2. Hu X, **Castellino SM**, Ji X. The lasting impact of the ACA: how Medicaid expansion reduces outcome disparities in AYAs with leukemia and lymphoma. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):10-19. doi: 10.1182/hematology.2024000528. PMID: 39644045; PMCID: PMC11665656.

e. Editorial and Commentaries:

i. Ji, X, Sohn H, Sil S, **Castellino SM**. Moving Beyond Patient-Level Drivers of Racial/Ethnic Disparities in Childhood Cancer. *Cancer Epidemiol Biomarkers Prev*. 2022 Jun1: 31(6):1154-1158 PMID 35642393
ii. Milgrom SA, **Castellino SM**. Shifting the Balance of Therapeutic Radiation in Adolescent and Young Adult Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep 2;34(9):1445-1447. doi: 10.1158/1055-9965.EPI-25-0902. PMID: 40891185.
iii. Forlenza CJ, **Castellino SM**. Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma. Transl Pediatr. 2025 Aug 31;14(8):1741-1745. doi: 10.21037/tp-2025-346. Epub 2025 Aug 27. PMID: 40949913; PMCID: PMC12433037.

f. Review Articles:

i. **Castellino S**, Hudson M. Health Issues in survivors of Childhood Cancer. *Southern Medical Journal* 95 (9): 977-984, 2002
ii. **Castellino SM,** McLean TW. Pediatric genitourinary tumors. *Curr Opin Oncol* 2007 19:248-253.
iii. McLean TW, **Castellino SM**. Pediatric genitourinary tumors. *Curr Opin Oncol* 2008; 20:315-20.
iv. **Castellino SM**, Martinez-Borges AR, McLean TW. Pediatric genitourinary tumors. *Curr Opin Oncol* 2009 21 (3):278-83
v. Parsons SK, **Castellino SM**, Yabroff KR. Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology. *ASCO Educational Book* 2018 May 23;(38):850-860. PMID:30231364
vi. **Castellino SM**, Parsons SK, Kelly KM. Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. Br J Haematol. 2019 Dec;187(5):573-587. doi: 10.1111/bjh.16197. Epub 2019 Sep 30. PMID: 31566730.
vii. Shaw PH, **Castellino SM**, Metts J, Guerrettaz R, Hayes-Lattin B, De Sa H, Bleyer A. Adolescent and Young Adult Oncology in the United States in 2025: Finding Its Place in the Oncology World-Part 1 of 2. J Pediatr Hematol Oncol.

2025 Aug 1;47(6):265-278. Epub 2025 Jun 20. PMID: 40549895.

viii. Shaw PH, **Castellino SM**, Guerrettaz R, Yeager N, Zebrack B, Brandon R, Bleyer A. Adolescent and Young Adult Oncology in the United States in 2025: Finding Its Place in the Oncology World Part 2 of 2. J Pediatr Hematol Oncol. 2025 Jun 9. Epub ahead of print. PMID: 40493815.

g. Book Chapters:

1. **Castellino SM**, Arkansas C, Grawe G, Cripe, T, Howard S. Myelodysplasia. In: Neish S (senior Ed). eMedicine Pediatrics. St. Petersburg: eMedicine Corporation, 2001
2. Dixon N, **Castellino SM,** Howard SC. Myelodysplasia. In: Neish S (senior Ed). eMedicine Pediatrics. St. Petersburg: eMedicine Corporation, 2010
3. **Castellino SM**, Hudson MM. Gastrointestinal and Hepatic Late Effects. In: Schwartz C (senior Ed). Survivors of Childhood and Adolescent Cancer (Springer 2015)
4. Ehrhardt M, Skinner R, **Castellino, SM**. Renal and hepatic late after childhood cancer. In Pediatric Clin North Am. 2020 Dec; 67(6):1203-1217. PMID: 33131542
5. **Castellino SM**, Nekhlyudov L, Ehrhardt M, Cherven B, Reagan P, Griggs J, Constine LS, Parsons SK. *Cancer Survivorship* (Ch 104) in Cancer: Principles and Practice of Oncology 12 e. Ed. DeVita, Lawrence, Rosenberg. Pubs Wolters Kluwer, Baltimore MD 2023. pp 1848-1856
6. Belsky J, **Castellino SM.** Hodgkin lymphoma. Rudolph Pediatrics 24th ed. 2024
7. Milgrom SA, Bates HE, Hall MD, Flerlage JE, **Castellino SM**, Constine LS. Lymphomas in Children, Adolescents, and Young Adults. In: Perez & Brady's Principles and Practice of Radiation Oncology. Ed(s) Halperin E, Wazer DE, Perez CA, Brady LW. Wolters Kluwer: Netherlands, 2025.

h. Books Edited and Written:

i. None

i. Book Reviews:

i. None

j. Manuals, Videos, Computer Programs, and Other Teaching Aids:

i. None

k. Published Abstracts:

1. Gentry T, McCowage G, Phillips K, **Castellino SM**, Hull S, Kurtzberg J, Gilboa E, Smith C. Multiparameter Fluorescence Activated Cell Sorting Analysis of Retroviral Vector Gene Transfer into primitive Umbilical cord blood cells. Blood 88: 435a, 1996.
2. Scaradavou A, **Castellino S**, Stevens C, Brochstein JN, Wagner J, Kletzel M, Rubenstein P, Kurtzberg J. Acute Lymphoblastic Leukemia in Infancy: Improved Outcome with Unrelated Placental Cord Blood (PCB) Transplants. Blood 1999.
3. Rusiñol AE, Thewke D, **Castellino SM** and Sinensky MS. Isolation and characterization of farnesylation specific H-ras-binding protein from HeLa cells. The FASEB Journal 15: A13, 2001
4. Kim J, Tegeler CH, **Castellino SM**, Shaw EG, Crutchfield K, Mozayeni R, Meads D, Likittanasombut P. Cerebral Hemodynamics evaluated by Dynamic Vascular Analysis TM in Pediatric Brain Tumor Survivors Treated with Cranial Irradiation. J Ultrasound Med 2006; 25; S 18-19.
5. **Castellino SM**, Tooze, J, Geiger A, Leisenring W, Goodman P, Mertens A, Stovall M, Robison L, Hudson M. Risks of Mortality in 5-year survivors of Hodgkin's Lymphoma in the Childhood Cancer Survivor Study (CCSS). Journal of Clinical Oncology May 2008, 26, n.15_suppl 1006

6. **Castellino SM**, Keller F, Dunphy C, McCarten K, Thomson J, Voss S, Nachman J, Constine L, Chen L, Schwartz C. Mixed cellularity (MC) histology confers favorable prognosis in Children and Adolescents with Low-Risk Hodgkin Lymphoma (HL). First International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma. Pediatric Blood and Cancer 2011 56(5), pp 876-894
7. Hudson M, Oeffinger K, Natha P, Mertens A, **Castellino S**, Mulrooney D, Gurney J, Armstrong G, Leisenring W, Robison L, Ness K. Longitudinal changes in health status of the Childhood Cancer Survivor Study cohort. Pediatric Blood Cancer; 2011:57(5)
8. Wilson CL, Leisenring WL, Oeffinger K, Nathan PC, Wasilewski-Masker K, Hudson MM, **Castellino, SM**, Armstrong GT, Brinkman TM, Robison LL, Ness KK. Predictors of declining levels of physical activity among adult survivors of childhood cancer. Journal of Clinical Oncology 31, no.15 suppl (May 20,2013)
9. Jordan JH, Morgan TM, Ellis LR, Lawrence J, Hall ME, **Castellino SM**, Hamilton CA, Torti FM, Vasu S, D'Agostino RB, Jr, Hundley WG. Pathologic atrophy of the left ventricular myocardium early after receipt of anthracycline-based chemotherapy. Circulation. 2013;128: A17537.
10. **Castellino SM** et. al. Outcomes and Patterns of Failure in Children/Adolescents with low-risk Hodgkin Lymphoma (HL) who are FDG-PET (PET3) positive after AVPC therap**y.** Klin Padiatr 2014; 226
11. Effinger K, Leisenring W, Oeffinger KC, Hudson MM, Ness KK, Marina N, **Castellino SM** Stovall M, Armstrong GT, Robison LL, Sainani K, Whittemore AS. Longitudinal Evaluation of Health Status in Aging Pediatric Hodgkin Lymphoma Survivors: Report from the Childhood Cancer Survivor Study. Klin Padiatr 2014; 226
12. Keller F, **Castellino SM** et.al Intensive therapy free survival (ITFS) for early-stage Hodgkin lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy alone. Klin Padiatr 2014; 226
13. Pauly M, Lee B, Travers C, Lew G, Sabnis H, **Castellino SM.** Prescribed Doses of Maintenance Oral Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia Varies by Patient Race. Pediatric Blood and Cancer 2016, 63 (S1)
14. **Castellino SM**, Pleasant K, Keyes G, Poehling K, Tooze JA. A Population Based Study of Uptake of Human Papilloma Virus (HPV) Vaccine in Cancer Survivors. Pediatric Blood and Cancer 2016 63 (S1)
15. Henderson*, TO, **Castellino*, SM**, Keller, FG, Kelly, K, Curtis, R, Conti, RM, Parsons, SK, Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III Clinical Trial for Advanced Stage Classical Hodgkin in Children and Adolescents. Dec. 2016 Blood 128 (22)
16. Kahn J, Kelly KM, Pei Q, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, **Castellino SM**. Survival by race/ethnicity in children and adolescents with Hodgkin lymphoma treated on cooperative group trials in the U.S. and Canada: A pooled analysis of Children's Oncology Group Trials. Blood 2017 130:1607
17. Effinger KE, Keller F, Bergsagel J, Lawrence T, Lewis R, Meacham L, Mertens A, **Castellino SM**. Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Treated with Contemporary Therapy. Blood 2017 130: 13466
18. Sabnis H, Keenum C, Lewis R, Silverman E, Patterson B, Effinger K, Bergsagel J, Mertens A, **Castellino SM.** Growth disturbances in pediatric patients receiving long term tyrosine kinase inhibitor therapy. Blood 2017 130: 13425
19. Kumar S, Travers CD, Bergsagel J, Keller FG, Pauly M, Sabnis H, **Castellino SM**, Lew G. Absence of Silent Inactivation Using Intravenous Pegasparaginase in Pediatric Acute Lymphoblastic Leukemia. Blood 2017 130: 1100
20. Miller L, **Castellino SM**, Mertens A, Keller F, Woods W. Incidence and predictors of adverse respiratory events during induction therapy in children with acute myeloid leukemia. December 2017 Blood 130 (s1):12590

21. Kahn J, Kelly KM, Pei A, Friedman DL, Keller F, Bush R, Bhatia S, Henderson TO, Schwartz CL, **Castellino SM**. Survival by age in children and adolescents with Hodgkin Lymphoma: A pooled analysis of Children's Oncology Group (COG) Trials. *Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 7543-7543.*
22. Parsons SK., Lerner D, Rodday AM, Curtis R, Kelly K, Conti, R, **Castellino SM**, Henderson TO. Parental work limitations at diagnosis of advanced stage pediatric Hodgkin Lymphoma – Results of caregiver work limitations questionnaire (CG WLQ). J*ournal of Clinical Oncology (May 20, 2018) 36*, no. 15_suppl
23. Oeffinger KC, Stratton K, Hudson MM, Leisenring W, Howell RM, Wolden SL, Constine LS, Diller L, Henderson TO, Sklar, CA, Nathan PC, **Castellino SM**, Barnea D, Smith SA, Armstrong GT, Robison LL. Risk-adapted therapy for pediatric Hodgkin lymphoma (HL) results in lower risk of late effects: a report from the Childhood Cancer Survivor Study (CCSS). J. Clinic Oncol. 2018; 36(15), 10510
24. **Castellino SM**, Rodday AM, Pei Q, Li M, Bush B, Keller F, Henderson TO, Kelly KM, Cella D, Parsons, SK. Performance of FACT-GOG-NTX to Assess Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Pediatric Hodgkin Lymphoma (HL). *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 10064.
25. Singh P, Wang X, Hageman L, Chen Y, Magdy T, Landier W, Ginsberg J.P, Neglia JP, Sklar C, **Castellino SM**, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Relling MV, Burridge P, Bhatia S. A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors: A COG ALTE03N1 report. *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 10030.
26. **Castellino SM**, Parsons SK, Pei Q, McCarten K, Kessel S, Punnett A, Horton TM, Henderson TO, Hodgson D, Dave H, Charpentier AM, Keller FG, Kelly KM, Children's Oncology Group. A randomized Phase III trial of Brentixumab vedotin (Bv) for de novo high-risk classical Hodgkin lymphoma (cHL) in children and adolescents- study design and incorporation of secondary endpoints in Children's Oncology group (COG) AHOD1331. Klinische Pädiatrie 2020; 232: 82-83
27. **Castellino S M**, LeBlanc M, Herrera A, Parsons SK, Punnett A, Hodgson D, Rutherford S., Kahn N, Constine L S, Davison K, Prica A Friedberg J, Kelly KM. An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826. Klinische Pädiatrie 2020; 232: 91-92
28. Dave H, Horton T M, Mai M, Saunders D, Jenkins G, Pei Q, Keller F G, **Castellino SM**, Kelly K M, Bollard C. Assessment of tumor antigen specific T cell immunity and cytokine milieu at diagnosis in patients with high-risk Hodgkin Lymphoma treated on Children's Oncology Group trial AHOD1331. Klinische Pädiatrie 2020; 232: 87
29. Hoppe BS, **Castellino SM**, Kessel S, Alazraki A, Voss S, Mhlanga J, Lai H, Eutsler E, Keller FG, Kelly KM, Cho S, McCarten. Impact of central review of imaging in an FDG-PET response adapted pediatric Hodgkin lymphoma protocol. S-IX-07 Klinische Pädiatrie 2020; 232: 111
30. Mailhot Vega RB, Hoppe BS, Hodgson D, Charpentier AM, Fitzgerald TJ, Kessel S, Pei Q, Keller FG, Parsons SK, Kelly KM, **Castellino SM**. Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA). Klinische Pädiatrie 2020; 232:103
31. Gravel, SB, Khandwala M, Wolden S, **Castellino SM**, Friedman D, Kelly KM, Robers K, Constine LS, Fitzgerald TJ, Hoppe B, Hodgson D. Reduction in Cardiac Radiation Dose Among Children Receiving Mediastinal RT: Reduction in Cardiac Radiation Dose Among Children Receiving Mediastinal RT: Comparison of Involved-Site vs Involved-field RT Delivered in Three Children's Oncology Group Trials. Klinische Pädiatrie 2020; 232:102
32. Kahn JM, Kelly KM, Pei Q, Friedman D, Keller FG, Bhatia S, Henderson TO, Schwartz C, **Castellino SM**. Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children's Oncology Group trials. S-X-04 Klinische Pädiatrie 2020; 232:112

33. **Castellino SM**, LeBlanc ML, Herrera AF, Parsons SK, Punnett A, Hodgson D, Rutherford SC, Khan N, Constine LS, Davison K, Prica AA, Friedberg JW, Kelly KM. An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. *Journal of Clinical Oncology (May 2020) 38, no. 15_suppl*
34. Smith SM, Sabnis HS, Lewis RW, Effinger K, Bergsagel J, Patterson B, Mertens A, Sakamoto KM, Schapira L, **Castellino SM**. Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors. American Society of Clinical Oncology Annual Meeting 2020 e22527(online publication)
35. Labudde EJ, DeGroote NP, Smith S, Ebelhar J, **Castellino SM**, Wasilewski-Masker K, Brock KE. Frequency and Timing of Palliative Opportunities in Pediatric patients with Hematologic malignancies. *Blood*. Amer Soc Hematology. 136:3 Nov 2020
36. Patel PA, DeGroote NP, Esbenshade AJ, Cash WT, **Castellino SM**, Jaggi P, Miller TP. Infectious Outcomes of pediatric Acute Lymphoblastic Leukemia Patients Presenting with Non-Neutropenic Fever. *Blood.* Amer Soc Hematology. 136:3 Nov 2020
37. Edington H, DeGroote N, Miller T, Stevenson J, Chandrakasan S, Mertens A, **Castellino S**. Predictors and Outcomes of Immunoglobulin Supplementation in B-Cell Acute Lymphoblastic Leukemia. Ped Blood Cancer 68(53) S53, June 2021
38. Stevenson J, DeGroote N, Choudhury T, Keller F, Brock K, Bergsagel DJ, Miller T, Cornwell P, Chonat S, **Castellino S**. Characteristics and Outcomes of Pediatric Oncology Patients at Risk for Transfusion Refusal. Ped Blood Cancer*,* 68 (53) S97 June 2021
39. Ebelhar J, DeGroote N, Labudde E, McCauley Massie A, Allen K, **Castellino S**, Wasilewski-Masker K, Brock K. Differences in Palliative Opportunities across Diagnosis Groups in Children with Cancer. Ped Blood Cancer*,* 68 (53) S85. June 2021
40. Ji X, Hu X, Lipscomb J, Mertens A, **Castellino SM**. "Utilization of Cardiac Surveillance in Pediatric Blood Cancer Survivors Who Received Anthracycline-Based Therapy Differs by Age: A Claims-Based Analysis." Blood. 2021 Nov 23;138:840.
41. **Castellino SM**, Pei A, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett, Dave H, Henderson TO, Hoppe BS, Charpentier AN, Keller FG, Kelly KM. Brentuximab vedotin Demonstrates Superior Event Free Survival in Pediatric High-Risk Hodgkin Lymphoma, / Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 7504-7504.
42. Ji X, Shi K, **Castellino SM**, Mertens A, Zhao J, Yabroff KR, Han X. "Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer." Journal of Clinical Oncology 40:2022 (suppl 16; abstr 1502). DOI: 10.1200/JCO.2022.40.16_suppl.1502.
43. Ji X, Shi K, **Castellino SM**, Mertens A, Zhao J, Yabroff KR, Han X. "Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer." Journal of Clinical Oncology 40:2022 (suppl 16; abstr 1502). DOI:10.1200/JCO.2022.40.16_suppl.1502.
44. Ji X, Hu X, Mertens A, Leisenring W, Nathan P, Armstrong G, **Castellino SM**, Kirchhoff A. "Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS)." Journal of Clinical Oncology 41:2023 (suppl 16; abstr 10011).
45. Han X, Shi K, Ruddy K, Zhao J, Mertens A, Yabroff KR, **Castellino SM**, Ji X. "Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer." Journal of Clinical Oncology 41:2023 (suppl 16; abstr 1509).
46. Ji X, Zhang X, Bai S, Stock W, Yabroff KR, Mertens A, **Castellino SM**. "Health insurance continuity and survival among children, adolescents, and young adults with blood cancer: An analysis based on SEER-Medicaid data." Journal of Clinical Oncology 41:2023 (suppl 16; abstr 6504).

47. **Castellino SM**, Ji X, Williamson Lewis R, Effinger KE, Mertens AC. “Impact of Survivorship Care Plans on Mortality in a Contemporary Cohort of Childhood Cancer Survivors.” JCO Oncology Practice 19:2023 (11_suppl; abstr 481).
48. Jain T, Ji X, Degroote N, Himes A, Coxhead C, Khanna A, Cathcart A, Miller T, Blum K, Tarquinio K, Mertens A, **Castellino SM**. “Association of Age with Acuity and Severity of Illness at Initial Presentation in Children, Adolescents, and Young Adults with Leukemia.” Blood 2023;142:3769.
49. Zhang X, **Castellino SM**, Yabroff KR, Stock W, Bai S, Mertens A, Lipscomb J, Ji X. “Health insurance continuity is associated with stage at diagnosis among children, adolescents, and young adults newly diagnosed with lymphoma.” Blood 2023;142:2390.
50. **Castellino SM**, Lewis R, Effinger K, Mertens A, Lipscomb J, Ji X. “Impact of Survivorship Care Plans (SCP) on Mortality in a Contemporary Cohort of Pediatric Patients Diagnosed with a Blood Cancer.” Blood 2023;142:3790.
51. Cathcart A, **Castellino SM**, Zhang L, Wasilewski-Masker K, Hong A, Sohn H, Ji X. “Association of residential economic and racial segregation with metastatic disease at diagnosis in pediatric patients with solid tumors.” In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B135.
52. Ji X, Zhang L, Han X, Sohn H, Meggett K, Lewis RW, **Castellino SM**. “Association of residential economic and racial segregation with pediatric cancer survival.” In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr A051.
53. Hu X, **Castellino SM**, Srivastava DK, Nathan P, Armstrong G, Mertens A, Kirchhoff AC, Ji X. “Adherence to guideline-recommended cardiac screening in Medicaid-enrolled survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).” JCO Oncology Practice 20:2024 (suppl; abstr 56).
54. Herrera AF, Leblanc M, **Castellino SM**, Li H, Rutherford S, Evens A, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano J, Mei M, Hess B, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz CH, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdury S, Brinker B, Sharma N, Singh A, Blum K, Perry A, Kovach A, Hodgson D, Constine L, Kostakoglu L, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl BS, Leonard J, Smith S, Kelly KM, Friedberg JW. “2-year follow-up of the S1826 study confirms improved progression-free survival with Nivolumab-AVD compared to Brentuximab Vedotin-AVD in advanced stage classic Hodgkin lymphoma.” Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
55. Flerlage J, Birz S, **Castellino SM**, Henderson TO, Lucas J, Renfro LA, Zhou Y, Volchenboum S, Furner B, Watkins M, Kelly KM. “Data collaborations accelerate pediatric Hodgkin lymphoma research through NODAL.” Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
56. Seelisch J, Hu B, Renfro LA, Keller FG, Duvall A, Henderson TO, Wu Y, Cho SY, Hoppe BS, Milgrom S, Roth LG, Grover NS, Lacasce AS, Kahn JM, Yao S, Parsons SK, Khan N, Mailhot Vega R, Hinds PS, Allen PB, Evens AM, Schoder H, **Castellino SM**, Kelly KM. “AHOD2131: A randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma.” Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
57. Rutherford S, Li H, Herrera AF, Leblanc M, Ahmed S, Davison K, Casulo C, Bartlett NL, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, **Castellino SM**, Kahl BS, Leonard J, Smith S, Friedberg JW, Evens A. “Nivolumab-AVD improves 2-year progression-free and overall survival compared to BV-AVD in older patients aged ≥60 years with advanced stage

classical Hodgkin lymphoma enrolled on SWOG S1826." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.

58. Giulino-Roth L, Melgar Toledo M, Keller FG, Hoppe BS, Forlenza C, **Castellino SM**, Andion Catalan M, Krystal J, Lamble A, Luisi F, Molina Morales F, Rao AV, Cooper S, Gonzalez-Llano O, Juarez Villegas L, Mauz-Körholz C, Shen J, Pillai P, Yusuf R, Kelly KM. "Updated results from the phase 2 KEYNOTE-667 study: Pembrolizumab in children and young adults with low-risk classical Hodgkin lymphoma and slow early response to front-line chemotherapy." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
59. Pabari R, Mccarten K, Flerlage JE, Lai H, Mauz-Körholz C, Dieckmann K, Palese M, Kaste SC, **Castellino SM**, Kelly KM, Stoevesandt D, Kurch L. "CNS involvement in pediatric Hodgkin lymphoma: A retrospective analysis of AHOD1331, EuroNet-PHL-C1 and EuroNet-PHL-C2 from SEARCH for CAYAHL." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
60. Williams A, Rodday AM, Renfro LA, Wu Y, Henderson TO, Keller FG, **Castellino SM**, Parsons SK. "Group-based trajectories of health-related quality of life among patients with high-risk pediatric Hodgkin lymphoma treated on the Children's Oncology Group AHOD1331 study." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
61. Hoppe BS, Milgrom S, Renfro LA, Wu Y, Schwartz C, Constine L, Hodgson D, Mccarten K, Kelly KM, Keller FG, **Castellino SM**. "Transplant-free salvage therapy for low-risk relapsed pediatric Hodgkin lymphoma: A sub-study of Children's Oncology Group AHOD0431." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
62. **Castellino SM**. Li H, Herrera AF, Punnett A, LeBlanc M, Parsons SK, Keller FG, Richard Drachtman R, Lamble A, Forlenza C, Doan A, Rutherford S, Evens A, Hodgson D, Little R, Smith M, Dillon H, Song J, Smith S, Friedberg JW, Kelly KM. "Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)." Abstract Book. HemaSphere 2024;8(Suppl 2): e70012. https://doi.org/10.1002/hem3.70012.
63. Ji X, Lewis RW, Jain T, Zhang L, **Castellino SM**. "Racialized economic and racial segregation is associated with acuity and severity of pediatric leukemia at presentation." Blood 2024;144(Suppl 1):3735.
64. Jain T, Ji X, DeGroote N, Himes A, Coxhead C, Lewis RW, Khanna A, Cathcart A, Miller T, Blum K, Tarquinio K, **Castellino SM**. "Acuity of illness at initial presentation mediates age differences in early mortality in pediatric and adolescent/young adult leukemia." Blood 2024;144(Suppl 1):2347.
65. Giulino Roth L, Melgar Toledo M, Keller FG, Hoppe B, Forlenza CJ, **Castellino SM**, Andión Catalan M, Krystal J, Lamble A, Luisi F, Molina Morales F, Rao AV, Cooper S, Gonzalez Llano O, Juarez Villegas L, Mauz-Koerholz C, Shen J, Pillai P, Yusuf R, Kelly KM. "Pembrolizumab in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma (cHL) and slow early response to front-line chemotherapy: Updated results from the Phase 2 Keynote-667 Study." Blood 2024;144(Suppl 1):462. DOI: https://doi.org/10.1182/blood-2024-199263 .
66. Stevenson J, Khanna A, Hawk A, Morse A, Alao O, Jordan K, Ji X, Sohn H, **Castellino SM**, Miller TP. "Association of race, ethnicity, and social deprivation on the incidence and severity of adverse events in induction in children with acute lymphoblastic leukemia." Blood 2024;144(Suppl 1):5110. DOI: https://doi.org/10.1182/blood-2024-205766.
67. Westmoreland KD, Taylor ZL, Miller TP, Chavana A, Rabin KR, Brown AL, Bernhardt MB, Schafer ES, O'Brien MM, **Castellino SM**, Ramsey LB. "Understanding the associations between high-dose methotrexate pharmacokinetics and the risk of adverse events in children and adolescents with Down syndrome associated high-risk acute lymphoblastic leukemia." Blood 2024;144(Suppl 1):1438. DOI: https://doi.org/10.1182/blood-2024-211870.
68. Muniz J, Ji X, Arellano M, **Castellino S**. "299 Patient and neighborhood characteristics associated with frontline therapeutic clinical trial enrollment among adolescents and young

adults (AYAs) with hematologic malignancies at affiliated pediatric and adult centers." Journal of Clinical and Translational Science 2025;9(Suppl 1):92. DOI:10.1017/cts.2024.935.

I. Other Publications:

i. Synergy News for Cancer Survivors, Wake Forest Baptist Health (2012)
-Childhood cancer Survivors
-The AWAKE Clinic- A Long term follow-up program for Childhood cancer Survivors

ii. **Castellino SM** & Shope S. "Gastrointestinal Health after Childhood Cancer." Children's Oncology Group Health Links, 2013. http://www.survivorshipguidelines.org/pdf/healthlinks/English/gastrointestinal_health_Eng.pdf. Revised October 2018

iii. Cherven, B. & **Castellino, S**. Cancer survivors Encouraged to receive HPV Vaccine. Geographic Health Equality Alliance, blog post, 2017. http://www.cadca.org/blog/cancer-survivors-encouraged-receive-hpv-vaccine

iv. Leukemia and Lymphoma Society. Reviewed by LaCasce, AS & **Castellino, SM**. "Hodgkin Lymphoma." Published online 2024. https://www.lls.org/sites/default/files/2024-04/PS57_Hodgkin_Lymphoma_2024.pdf.

v. Heneghan MB, **Castellino SM**, Thompson LA. What Is Childhood Lymphoma? JAMA Pediatr. 2024;178(11):1234. doi:10.1001/jamapediatrics.2024.3614.

III. Contributions Not Otherwise Noted:

i. None